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On World Malaria Day April 2010, impetus has been towards reducing Malaria burden in 
2010 to half as compared to the year 2000 levels and to achieve eradication of malaria by 
2015 through progressive elimination methods1. These methods rely heavily upon effective 
and efficient diagnosis of the parasite making it a crucial step towards early identification, 
control and subsequent elimination of the disease. The gold standard for malaria diagnosis 
still continues to be optical microscopy, although it has severe limitations due to its ease of 
availability, labor intensive process and need for highly skilled technicians.  The emergence 
of chloroquine resistant strains in 1957and the further discovery of multi-drug resistant strains 
(MDRSs) and recent Artemisinin resistant strains3 in 2009 along the Thai-Cambodian border, 
has been a cause of grave concern. The current diagnostic techniques do not address the 
above need for differentiating sensitive vs resistant strains of the parasite, which would be an 
important factor in determining the clinical administration of the effective drug. My current 
thesis involving “Synthesis of fluorescent anti-malarial drug probes and evaluation within 
plasmodium falciparum” addresses the above requirement for a robust, fast, sensitive, & 
portable diagnostic technique for determination of drug resistant Plasmodium falciparum 
strains within patient blood samples. The probes designed would help in reliable data 
collection and administration of the appropriate drug dosage. The thesis discusses the drug 
design rationale, synthesis and results of the application of the probes in (1) malaria diagnosis 
(in collaboration with Dr. Kevin Tan), (2) cancer studies (in collaboration with National 
Cancer Institute, USA) and (3) bio-imaging studies on macrophages (studies done by myself 
in collaboration with Dr. Kevin Tan). The probes are mainly designed on chloroquine and 
artemisinin analogues, which are the preliminary drugs administered for the treatment of 
malaria. The probes tested on Plasmodium falciparum & mammalian cell lines established 
their lysosomotropic nature thus providing potential insight into the pathway within the 
parasite and macrophages. The future lies in utilizing the concept of drug probes or 





A deadly mosquito borne disease, “Malaria” was the cause of 7% of global deaths in 
children in 2008. According to WHO estimates last year malaria accounted for 250 
million cases which lead to 850,000 deaths worldwide in the developing countries, 
especially Africa. Global Malaria commitment and funding has increased 10-fold to 
about US$1.8 billion accounting for external funding sources and other donors like 
GFATM (The Global Fund to Fight Aids, Tuberculosis and Malaria), UNITAID, US-
PMI. On World Malaria Day April 2010, impetus has been towards reducing Malaria 
burden in 2010 to half compared to 2000 levels and to achieve eradication of malaria 
by 2015 through progressive elimination methods1 as described in Fig. 1  
 
Fig.1 – WHO Roll back Malaria goals3 
 
The intervention methods coupled with better diagnostic techniques have shown 
success in the past 6 years (2000-06) by reduction in malaria burden by 50%2. The 
challenges for achieving WHOs goal of control, elimination and subsequent 
eradication of malaria lies in making improvements in the following tools3: 
a) SERCaP (Single Encounter radical cure and prophylaxis). 
b) VIMT (Vaccines that interrupt malaria transmission). 
c) Vector Control techniques. 
d) Improved diagnostics and surveillance. 
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a) SERCaP – The objective of SERCaP type of drug would be to provide radical cure 
and prophylaxis for a period of at least 1month outlasting the typical development 
period of P.falciparum parasites. Chloroquine and derivatives, quinine and 
artemisinin were the first line of defence against malaria due to their clinical 
effectiveness and low-cost. Fig 2 highlights the year of introduction of anti-malarial 
drugs administration and the subsequent clinical observations of emergence of 
resistant strain4 denoted by the suffix “R” after every drug., e.g. – “CQ- 
Chloroquine” was introduced as the drug of choice for administration to malaria 
patients in 1945 and subsequently in the year 1955-1960 “CQR – Chloroquine 
resistance” due to emergence of chloroquine resistant strains of parasites was 
observed. (Abbreviations of other drugs are enclosed in List of Abbreviations IV-V) 
 
Fig.2 – Anti-Malarial drug introduction and emergence of resistance4 
 
Fig. 3 highlights the mode of action of various anti-malarial drugs within the parasitic 
cellular components5. It is interesting to note that respite the varied mode of action of 
the above mentioned drugs, the parasite was still successful to genetically modify its 
cellular components to give rise to the drug specific or even multi-drug resistant 
strain. The emergences of multiple drug resistant strains (MDRSs) have been 
attributed to the single dose therapies or improper dosages. These have led to 
recrudescence i.e. generation of mutant plasmodium strain4. 




Fig.3 – Intra-erythrocytic P.falciparum trophozoite and anti-malarial drug targets5 
 
The amino acid mutations in the cell components of the P.falciparum parasites from 
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Dihydroartemisinin       α-Artesunate 
 
 
Reports from 1995-2010 extensively highlight research contributions into new drug  
development6-11, typically by utilizing active components from medicinal plants and 
marine natural products, which have been recommended as replacements for existing 
anti-malarial therapeutics. The molecules cover wide range of structures like alkaloids 
(16), peptides (17), flavonoids (18), limonoids (19), quinones (20), terpenes (21), 
trioxolanes (22), poly-ether type SF2487 (23)6-11. 
              
      
    
















Table 1: Genetic changes in P.falciparum associated with resistance to current drugs. 
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Since malaria remains confined to developing or third-world nations, cost 
effectiveness, ready availability and clinical suitability of the above highly efficacious 
anti-malarial agents are the most important factors for successful implementation.   
Thus WHO has recommended use of artemisinin combination therapy (ACT) to 
contain the emergence of resistant strain. 
 
Fig. 5 – Artemisinin combination therapy (ACT). 
Fig. 5 above shows combination therapies of artesunate with various anti-malarial 
drugs (as depicted by arrows) recommended by WHO.  
Artemisinin multiple mode of action was expected to discourage the emergence of 
artemisinin resistant strains. Unfortunately, the discovery of existence of artemisinin 
resistant strains in 2009 and 2010 along the Thai-Cambodian border has been a cause 
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b) VIMT (Vaccines that interrupt malaria transmission) – The existing vaccines in 
clinical development have the objective of reducing morbidity and mortality in young 
children in highly endemic countries. However future vaccines are expected to 
function as VIMT’s with the ultimate of purpose of complete eradication. Vaccine 
development18-20 has taken a great leap with certain vaccines already reaching Phase 
III trials of testing. These vaccines are expected to create an immunological response 
to two specific parasite surface proteins namely MSP-1 (merozoite surface protein) 
and CSP (circumsporozoite protein). The vaccine RTS/S (from GlaxoSmith Kline 
based on CSP) has shown 65% efficacy and has currently progressed to Phase III 
clinical trials. First yet unsurpassed success in inducing complete and permanent 
protective immunity responses against malaria was achieved with irradiated 
sporozoites in human studies. However mass production of these sporozoites still 
remains a challenge. Other vaccination techniques are summarized below (Table 2). 
 
c) Vector Control techniques – These techniques rely upon interventions like indoor 
residual insecticide spraying and insecticide treated bed-nets to reduce vector daily 
survival rates. The challenge lies in developing broader ranges of insecticides that can 
circumvent emerging resistance to existing insecticides. The other challenge lies in 
the development of interventions for vectors that do not lie or feed indoors3. 
 
d) Improved diagnostics and surveillance – Current methods for measuring 
transmission are time consuming, expensive and have low sensitivity for use in 
conditions of low and non-uniform infection. The main challenge for achieving 
eradication lies in creating a robust, sensitive and specific standardized method for the 
assessment of transmission intensity in the intervening period of low and non-random 
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levels of transmission3. The diagnostic methods are effective, but do not provide fast 
diagnosis and have to rely upon highly skilled technicians. The current gold standard 
 
Table 2:  Vaccination techniques and parasite targets20. 
 for malaria diagnosis has been optical microscopy, but this has limitations due to its 
ease of availability, labor intensive process and need for a highly skilled technician. 
The WHO (World Health Organization) along with FIND (Foundation for Innovative 
New Diagnostics) have started evaluations of rapid diagnostic tests (RDTs) since 
2008 in order to provide for fast, accurate, sensitive and affordable tools for the 
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instant evaluation of blood samples in the field. In 2010 from the 29 diagnostic tests 
submitted for analysis 15 have met the minimum performance criteria as per WHO 
guidelines based on RDTs21,22. The RDTs are based on the detection of plasmodium 
specific antigens in the whole blood specimens. These are available in dipstick, 
cassette or card format and contain bound antibodies to specific antigens such as 
histidine-rich proteins-2 (HRP2) (specific to P.falciparum), pan specific or species 
specific plasmodium lactate dehydrogenase (pLDH) or aldolase (specific to all major 
plasmodium species : P.falciparum, P.vivax, P.ovale, P.malariae)15. These RDTs are 
sensitive towards test environment and conditions. The existing diagnostic tests for 
malaria along with my proposed method have been summarized in the Table 323. 
 
Methods for Malaria and Drug Resistance Diagnosis 
 
Factors 
In vivo  
response 


















Cost High Low High High Low Low 
Time for 
results 
Days 48 hrs 48 hrs 12 hrs 0.5 hrs 4 hrs 
Skill level High High High Moderate Moderate Moderate 












MDRSs ID Yes No Yes Yes No YES 
Portability NA No No No Yes YES 
++ - low sensitivity 
 +++ - high sensitivity 
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HYPOTHESIS & OBJECTIVES - 
This thesis covers the design, synthesis and biological applications of fluorescent anti-
malarial probes24,25,26, by addressing the key requirements for robust, sensitive, fast 
and portable diagnostic. The idea of using fluorescent drug probe has not gained 
popularity due to change in the final pharmacophore thus influencing the binding  
property of the final molecular structure24. Chloroquine is very well known for its 
lysosomotropic (accumulation in the food vacuole of the parasite) and heme-binding 
pathway of action within the chloroquine sensitive parasite. However these features 
have never been exploited towards diagnosis for identifying resistant strain26. 
Artemisinin and its derivatives have a wide range of mode of action within the 
parasite. There are still ongoing debates on the modes of action of artemisinin and its 
bio-activation pathways within the plasmodium parasite. Meshnick’s heme-iron 
triggered bio-activation of trioxanes to form reactive oxygen species27, Posner and 
Jefford’s reductive scission model28, Haynes and co-workers open peroxide model29 
and iron vs heme dependant bio-activation30, inside parasite cells all suggests that 
there is not a single pathway for the activation of artemisinin. The binding site of 
artemisinin is not clearly understood and is proposed to inhibit the sarcoplasmic 
reticulum Ca2+ - transporting ATPases (SERCAs) specifically within the parasites 
(PfATP6)31-33. Artemisinin has also been found to have increasing importance for 
their application as anti-cancer drug that act upon drug and radiation resistant tumour 
cell lines. The mode of action is again proposed to be endo-peroxide mediated with 
the end result of decreased proliferation, increased oxidative stress, induction of 
apoptosis and inhibition of angiogenesis thus leading to cytotoxicity in tumour 
cells27,34. Clearly with the recent discovery of artemisinin sensitive strains it would be 
increasingly important to understand the mode of action of artemisinin within the 
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resistant parasites. Thus, chloroquine and artemisinin (mainly Artesunate, Artelinic 
acid and Deoxocarbaartemisinin) analogue based probes were synthesized for 
diagnostic and bio-imaging application as shown in Fig. 6 
                     
Chloroquine         α–Artesunate    β-Deoxocarba-      β-Artelinic 
            diphosphate           artemisinin                      acid 
 
Fig.6   Molecular structures of parent drug molecules. 
The model for design and synthesis of fluorescent anti-malarial probe can be 
described as below. 
 
       Drug                     Linker            Fluorescent Dye 
Fig.7   Diagrammatic representation of fluorescent drug probes. 
My method of utilizing fluorescent anti-malarial probe for diagnosis provides the 
health worker on the field with a portable tool for malaria detection and identification 
of multi-drug resistant strains (MDRSs). This would help in reliable data collection 
and administration of the appropriate drug regime based on the type of drug resistance 
identified in the parasite. It would also provide personal healthcare, reduce the burden 
of drug inventory in hospitals and control the further spread of MDRSs, thus modestly 
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RESULTS AND DISCUSSIONS 
3.1 Proposed Synthetic route – 
3.1.1 Synthesis of probes 36a, 36b and 4235-37 – 
The synthesis of probes (36a, 36b and 42) is divided into synthesis of the chloroquine 
precursor (28a, 28b) and the coumarin precursor (35, 41). Nucleophilic substitution 
on 4,7-dichloroquinoline (26) using 1,2-diaminoethane and 1,4-diamino butane gave 
analogues (27a) and (27b) respectively. Due to the quinoline structure it is easy to 
replace the labile chlorine atom at 4-position compared to the one at the 7-position. 
Further addition reactions using bromo ethane gave the chloroquine precursor (28a 
and 28b) and diethyl (29a and 29b) precursor of chloroquine.  Direct addition of 
bromoethane led to diethyl chloroquine analogues in reasonable yields.   Hence slow 
addition and dilution of bromoethane in anhydrous DMF is an important step to 
increase the yields of formation of the desired chloroquine precursor versus the 
diethyl analogues. An alternative technique for synthesis of chloroquine precursor 
(28a and 28b) was defined and scale up synthesis up to 1gm with almost 90% yields 
was achieved. Mono-boc analogue of 1,2-diaminoethane was synthesized by slow 
addition and dilution (in anhydrous CH2Cl2) of boc-anhydride into excess of diamine 
(also diluted in anhydrous CH2Cl2). Activation of the carboxylic group in bromoacetic 
acid using reagents 2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium 
hexafluorophosphate methanaminium (HATU)) + 1-Hydroxy-7-Azabenzo- triazole 
(HOAt) in presence of base diisopropylethylamine (DIPEA) and coupling to mono 
boc protected 1,2-ethanediamine gave the acetamido analogue (33). HATU + HOAt 
reagents for activation of carboxylic group were preferred over DCC + HOBt or other 
similar reagents, due to high yields and ease of work-up. The linker (33) is further 
deprotected using trifluoroacetic acid in anhydrous CH2Cl2 to give the trifluoroacetic 
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salt of the amine, which upon neutralization with excess DIPEA is again coupled with 
coumarin-4-acetic acid (34) using HATU + HOAt reagents to give the coumarin 
precursor (35). This bromo acetamido coumarin precursor (35) is purified by column 
chromatography and used immediately without storage due to its inherent instability. 
Finally nucleophilic substitution of the labile bromine atom by the amine group (28a, 
28b) in the presence of dry potassium carbonate and anhydrous acetonitrile (ACN) 





Scheme 1 – Chloroquine-coumarin probe synthesis 1 
 




Scheme 2   – Chloroquine-coumarin probe synthesis 2 
3.1.2 Synthesis of probes (48a and 48b)38 – 
Dess-Martin Periodinane reagent was used for reduction of fmoc protected 3-amino 
propanol because it was found to be milder method over chromium based reductions, 
ease of work-up and sensitivity of the aldehyde precursor (45). Sodium 
triacetoxyborohydride in anhydrous CH2Cl2 was used for reductive amination reaction 
between aldehyde (45) and amine analogue of chloroquine (28a, 28b). The reaction 
progresses by formation of imine upon addition of aldehyde and this intermediate is 
reduced to the desired product (46a, 46b) on addition of NaBH(OAc)3. Sodium 
triacetoxyborohydride is a mild reducing agent and excess reagent can easily 
quenched with methanol, which affords cleaner work up and high yields of the desired 
product in comparision to other hydride reducing agents. Upon fmoc de-protection the 
amine was directly used after short column purification for the final coupling process, 
due to its high affinity towards the silica column. The low yield of probes (48a, 48b) 
was possibly due to the mild coupling method adopted and low reactivity between 
(47a, 47b) and coumarin-4-acetic acid (34).  
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Scheme 3   – Chloroquine-coumarin probe synthesis 3 
 
3.1.3 Synthesis of probes 49a and 49b – 
Dicyclohexylcarbodiimide (DCC) + hydroxybenzotriazole (HOBt) with DIPEA in 
anhydrous DMF as solvent gave good yields of probes 49a (55%) and 49b (60%) in 
comparision to HATU + HOAt reagents. The above reagents follow the same 
mechanism of formation of activated carboxylic acid ester, which upon reaction with 
amine (28a, 28b) gave the desired product (49a, 49b). 
 
 
Scheme 4   – Chloroquine-coumarin probe synthesis 4 
3.1.4 Synthesis of probe 51, 53, 5539 – 
Amide coupling method used for synthesis of probes 48a, 48b was used for synthesis 
of probes 51, 53, 55. In the case of probe 55a and 55b, the amine was isolated by 
treatment of the TFA salt with bicarbonate solution at 0oC and then coupled with 
BODIPY-COOH using HATU+HOAt coupling technique. 
 
 


























Scheme 6 – Artesunate-coumarin probe synthesis 2 
 
Scheme 7 – Chloroquine-BODIPY based probes. 
 
3.1.5 Synthesis of artelinic acid probe (57, 83, 86 )40 – 
Mixture of dihydroartemisinin epimers was reacted with 4-(hydroxy methyl) benzoic 
acid in the presence of Lewis acid boron trifluoride etherate to preferentially give the 
β–Artelinic acid (56). The reaction proceeds via formation of oxy-carbenium species 
on addition of boron trifluoroetherate. 4-(hydroxymethyl) benzoic acid is only able to 
approach the oxy-carbenium ion from the 10β-position due to possible steric 
hindrance by the endoperoxide arrangement. Thus it selectively yielded β–Artelinic 
acid (56).    Method adopted for synthesis of artesunate probes (51, 53) was used for 
synthesis of artelinic acid based probe (57). However TAMRA analogue for coupling 
with artelinic acid was synthesized using mixed anhydride method as shown below 
followed by HATU+HOAt coupling to give TAMRA-Artelinic probe (83). 
 






Scheme 8 – Artelinic acid based probes. 
3.1.6 Synthesis41 of click probes 58-60, 61-64, 87-90, 104-105 – 
Amide coupling method used for synthesis of probes 48a, 48b was used for synthesis 
of probes 59-62. Probes 58, 63a, 63b, 64a and 64b utilized similar nucleophilic 
substitution method as adopted during synthesis of probes 36a and 36b.   
 





            
         
 
 





     
 
        Scheme 9 – Click chemistry enabled probes. 
 
3.1.7 Synthesis of BODIPY fluorescent probes 91 – 
Due to the problems associated with the isolation of amine precursor after Fmoc 
deprotection, a second strategy of synthesis of boc analogue (80) of chloroquine 
precursor was adopted. This was further deprotected with trifluoroacetic acid at 0oC 
and then the salt obtained was directly used for further coupling reaction by 
neutralization with DIPEA at 0oC as shown in Scheme 10.  
 




Scheme 10 –BODIPY chloroquine probe 
 
3.1.8 Synthesis of Deoxocarbartemisinin probes (98 and 100) – 
Deoxocarbaartemisinin intermediate was synthesized as per procedure enclosed in 
literature. The synthesis of final probes follows the same procedure as used for 
synthesis of artelinic acid probes. The detailed synthesis is shown in Scheme 11. 
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3.2  Drug design rationale and IC50 values – 
The proposed drug design was expected to have the following properties  
1) Minimal modification of the parent drug molecule structure. 
2) Efficacy of the final probe would be similar to the parent drug molecule. 
3)   Fluorescent dyes selected would not show any activity with the Plasmodium  
falciparum parasite as cultured in the lab. Coumarin-4-acetic acid 34, Borondipyrro 
methane carboxylic acid (BODIPY-COOH) 84, Tetraaminomethylrhodamines  
carboxylic acid (5-TAMRA COOH  and 6-TAMRA COOH 81) have no activity  
within the parasite. 
4) High thermal and hydrolytic stability for applications in biological systems. 
5) High fluorescence quantum yields confer live-cell imaging capability42,43. 
   
                           Probe design 1              Probe design 2 
    
            
      Probe design 3                  Probe design 4 
 
       
   
       α-Artesunate probe design 1                    α-Artesunate probe design 2 
 
            Fig.8   Proposed drug design for probes 
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β-Artelinic acid probe design   β-Deoxocarbaartemisinin carboxylic acid  
 
   Fig.8   Proposed drug design for probes 
The proposed drug design was analyzed for its IC50 activity on chloroquine sensitive 
Plasmodium falciparum (3D7) as cultured in lab. As expected from the proposed 
design the tertiary amine functionality of the chloroquine was critical to the activity 
inside the parasite thus probes 36a (IC50= 349nM), 36b (IC50= 230nM), 48a (IC50= 
85nM) have values closer to the parent drug molecule (chloroquine diphosphate (4), 
IC50 = 23nM). Variation was also observed when the chain length was increased from 
2 carbon 48a (IC50= 85nM) to 4 carbon 48b (IC50= 1200nM). The dioxaoctane linker 
42 (IC50= 230nM), also lead to difference in IC50 values. This design could assist in 
fishing out enzymes using immunoprecipitation technique due to the large spacing 
between drug and the fluorescent-affinity probe but cannot be utilized in diagnosis.  
IC50 values of other probes are summarized in Fig. 9 below. 
  
         
    Chloroquine diphosphate 
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     α-Artesunate 
Fig.9   IC50 values of proposed probes. 
Thus, as per the above proposal, chloroquine probe designs 1 and 3 are best suited for 
diagnostic applications. Artesunate probe design 1 showed good activity within both 
P.falciparum and cancer cell lines (discussed in NCI studies section 3.6). However it 
was observed by LCMS (as observed during thermal stability studies section 3.3) that 
there was a distinct possibility of cleavage of the fluorescent tag within the parasite. 
This has also been confirmed by reports that artesunate has a relatively short half life 
(~10min) and that the dihydroartemisinin fragment is the actual active component 
(half life ~ 1hr). Thus I further proposed two modifications to the artesunate based 
structure : one by replacing succinate fragment in artesunate with a para benzoxy 
carboxylic acid fragment also known as β- Artelinic acid 56 and the other by 
replacing the oxygen at 10 position with carbon also known as Deoxocarbaartemisinin 
carboxylic acid 65. These intermediates have been thoroughly studied for their 
hydrolytic stability (β- Artelinic acid 56 has half life of 13hrs in acidic pH; 
Deoxocarbaartemisinin carboxylic acid 65 has a half life of 300hrs in acidic pH) 











15, IC50 = 24nM
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parasite for the above molecules has not been studied. The design of the final probes 
(57, 83, 86, 92.93)   is based on the above discussed parent molecules.  
    
     Alkyne - Chloroquine      Alkyne – Coumarin      Azide – Coumarin 
 
        
            Alkyne - β-Artelinic acid   Azide - β-Artelinic acid  
 
    
Fig. 10 – Probe Design for Click Chemistry 
Click chemistry enabled probes have also been synthesized for bio-imaging, binding 
studies and enzyme fishing for in-vitro applications. Examples of click enabled 
molecules are shown in Fig. 10. Later sections in this thesis show that short term 
thermal stability (4days) of the probes presented in Fig. 10 have shown that they are 
resilient for applications in many biological protocols. Thus, the above drug design 
covers a considerable range of molecules to assist in diagnostic, bio-imaging and 
pathway elucidation studies for understanding diseases within P.falciparum, cancer 











Page 24 of 219 
 
 
3.3 Thermal Stability Protocol for Drug Probes – 
Thermal stability study was designed based on the ICH guidelines for pharmaceutical 
drug analysis46. The above studies clearly indicate thermal stability for 36a, 36b and 
48a probe structures. (The shift in retention time can be attributed to the pressure 
imbalance in the column but the overall mass values for the peaks are consistent 
across all tests). However the artesunate based probes are not as stable as the 
chloroquine based probes as observed in both thermal and hydrolytic studies. 
Nevertheless the thermal stability tests established that the probes (36a, 36b and 48a) 
are stable under normal packaging conditions and are suitable for field requirements. 
The integration area under the curve represents 95-98% of the probe concentrations 
and is consistent as compared with the standard. Data for 4 days thermal stability 
studies on the artelinic acid (56), artelinic acid based probe (57) and click chemistry 
probes (58–64) are enclosed in Appendix 1. Although the above probes have shown 
excellent thermal stability for 4 days, long term stability data (6months, 1year) needs 
to be established for understanding packaging requirements for the same. 
3.3.1 Thermal Stability studies for Structure (36a) – 
 
 
MS (E+)   Ret. Time: 8.460 -> 8.473 - 8.333 <-> 8.753 
     

















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 36a (Standard) 




MS (E+) Ret. Time: 10.000 -> 10.013 - 9.827 <-> 10.720 
                              
                         MS (E+)   Ret. Time: 9.973 -> 9.987 - 9.813 <-> 10.547 
MS(E+)   Ret. Time : 9.267 -> 9.280 - 9.120 <-> 9.567 
 





















Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – 37oC, Humidity –100% 
Structure 36 a  2months 


















Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36 a   
(4days) in 100µL DMSO 



















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 36a  (4 days) 




MS(E+)   Ret. Time : 9.193 -> 9.207 - 9.087 <-> 9.447 
MS(E+)   Ret. Time : 9.153 -> 9.167 - 9.020 <-> 9.540 
 
 
MS(E+)   Ret. Time : 8.940 
Fig. 11 – LCMS Analysis probe 36a (Eluent – ACN +0.1% TFA: H2O + 0.1% TFA) 
















1.2 mAU (x1,000)254nm,4nm (1.00)























Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – 37oC, Humidity –100% 
Structure 36a  (4months) 
















4.0 mAU (x1,000)254nm,4nm (1.00)
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36a  (2months) in DMSO 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36a  (4months) in DMSO 
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3.3.2 Thermal Stability Studies on Structure (36b) – 
 
 
MS (E+)   Ret. Time: 8.880 -> 8.893 - 8.727 <-> 9.207   
 
MS (E+)   Ret. Time: 10.227 -> 10.240 - 10.060 <->10.540 
 
MS (E+)   Ret. Time: 10.173 -> 10.187 - 10.000 <-> 10.760 
      

































Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 36b  (4 days) 




















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 36b  (Standard) 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36b  (4d) in 100µL DMSO 
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MS(E+)   Ret. Time : 9.380 -> 9.393 - 9.260 <-> 9.653 
         
MS(E+)   Ret. Time : 9.433 -> 9.447 - 9.293 <-> 9.880 
  
    
MS(E+)   Ret. Time : 9.380 -> 9.393 - 9.287 <-> 9.660 
     
 

















































































Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 36b  (2 months) 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36b  (2months) in DMSO 
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 36b  (4 months) 
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 36b  (4 months in DMSO) 
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MS(E+)   Ret. Time : 9.260 -> 9.273 - 9.073 <-> 9.647 
MS(E+)   Ret. Time : 9.340 -> 9.353 - 9.200 <-> 9.680 
Fig. 12 – LCMS Analysis probe 36b (Eluent – ACN +0.1% TFA: H2O + 0.1% TFA) 
 
3.3.3 Thermal Stability Studies on Structure 48a – 
 
 
MS (E+)   Ret. Time: 8.720 -> 8.733 - 8.553 <-> 8.980 
Fig. 13 – LCMS Analysis probe 48a (Eluent – ACN +0.1% TFA: H2O + 0.1% TFA) 



































1.0 mAU (x1,000)254nm,4nm (1.00)









Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 48a  (Standard) 
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 36b  (6 months) 




MS (E+)   Ret. Time: 8.747 -> 8.760 - 8.587 <-> 9.240 
                                
MS(E+)   Ret. Time : 8.720 -> 8.733 - 8.593 <-> 9.033 
                               
MS(E+)   Ret. Time : 8.687 -> 8.700 - 8.487 <-> 9.280 
 
Fig. 13 – LCMS Analysis probe 48a (Eluent – ACN +0.1% TFA: H2O + 0.1% TFA) 






















































Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 48a  (4 days) 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 48a  (4d) in 100µL DMSO 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 48a  (2months) 
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MS(E+)   Ret. Time : 8.720 -> 8.733 - 8.547 <-> 8.980 
MS(E+)   Ret. Time : 10.107 -> 10.120 - 9.933 <-> 10.987 
MS(E+)   Ret. Time : 8.693 -> 8.707 - 8.553 <-> 9.340 
 













Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 48a  (6 months) 





















Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 48a  (4months) in DMSO 














4.0 mAU (x1,000)254nm4nm (1.00)




















Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 48a  (2months) in DMSO 
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 48a  (4 months) 
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                               MS(E+)   Ret. Time : 9.367 -> 9.380 - 9.193 <-> 9.813 
                             MS(E+)   Ret. Time : 9.353 -> 9.367 - 9.200 <-> 9.713 
 Fig. 13 – LCMS Analysis probe 48a (Eluent – ACN +0.1% TFA: H2O + 0.1% TFA) 
3.3.4 Thermal Stability Studies on Structure 51 – 
As shown by thermal studies on artesunate probe 51, the probe is unstable after 4 days  
of heat treatment as per standard conditions. This was expected due to the acid labile  
nature of the ester bond between artesunate and coumarin linker precursor (50).  
 
 
MS(E+)   Ret. Time : 8.533 -> 8.547 - 8.413 <-> 8.773 






2.5 mAU (x1,000)254nm,4nm (1.00)


















4.0 mAU (x1,000)254nm,4nm (1.00)
Conditions 
Amount – 3mgs (95%)  
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 48a  (6months) in DMSO 









Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 51  (Standard) 




MS(E+)   Ret. Time : 12.860 -> 12.873 - 12.740 <-> 12.887. 
                            
MS(E+)   Ret. Time : 11.107 -> 11.120 - 10.967 <-> 11.193 
                                
MS(E+)   Ret. Time : 14.953 -> 14.967 - 14.807 <-> 15.000 
 
Fig. 14 – LCMS Analysis probe 51 (Eluent – ACN: H2O) 
Thus I have proposed and synthesized artelinic acid and β–Deoxocarbaartemisinin 
carboxylic acid based probes (57, 83. 86, 98, 100), which should have high thermal 
and hydrolytic stability, compared to the above artesunate based probe 51. Thermal 
stability data for remaining probes is enclosed in Appendix 1.  























Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 51  (4 days) 
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3.4   Plasmodium studies – 
The probe 36b was analyzed for its ability to differentiate between chloroquine 
sensitive versus chloroquine drug resistant strains as shown in Fig.15. 
The chloroquine resistant strains do not uptake chloroquine probe 36b as compared to 
chloroquine sensitive ones. This selective efflux is due to mutations in PfCRT 
(Plasmodium falciparum chloroquine resistant transporter) in the drug resistant 
strains47. This establishes a crtical component for diagnosis of drug sensitive over 
resistant strains.  
 
Fig. 15 – Differential staining47 by structure 36b in 3D7 (chloroquine sensitive), 7G8,   
                K1 and K1+VP strains of Plasmodium falciparum Fig.15 clearly shows that  
 
the anti-malarial fluorescent probe can selectively identify chloroquine sensitive 
strains of P.falciparum by higher % of staining vs Hoechst stain with increasing 
concentrations of the probe. The optimal working concentrations for the probe were 
identified to be 3µM to 6 µM. The above flow cytometry data was supported by 
confocal imaging study on the probe. Thus the lysosomotropic property of the probe 
can be effectively utilized for diagnosis. The imaging studies47 on the chloroquine 
sensitive 3D7 P.falciparum strain using chloroquine probe 36b are shown in Fig.16  




0 nM           30 nM        300 nM         3µM           30 µM           300µM 
Concentrations of Chloroquine Probes 
Fig. 16 – Imaging47 of Chlorquine probe 36b at different concentrations 
The confocal imaging studies show that the chloroquine probe 36b accumulates in the 
food vacuole of the parasite at low concentrations (mainly 300nM to 3µM) as 
compared to JC-1 red and JC-1 green probes, which stain the other cell components of 
the parasite. The above concentrations can be considered to be the optimum for 
confocal imaging for the identification of chloroquine sensitive versus chloroquine 
resistant strains of P.falciparum. However, at high concentrations (mainly 30 µM and 
300 µM) the probe starts to stain the entire parasite non-selectively. Thus we could 
effectively analyse parasite strains at a lower concentration of probe. However, 
coumarin based probes cannot be used for live-cell imaging studies due to the 
sensitivity of the probe and the cells to blue laser irradiation. Chloroquine –BODIPY 
based probe 55 was synthesized and used for live-cell bio-imaging study on 
P.falciparum 3D7 strain as shown in Fig. 17. This experiment was performed on the 
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– BODIPY probe 55 were used for varying time periods to study the effects of the 
concentrations on the digestive vacuole of the parasite. The results show that 2µM is 
the optimal concentration of the probe at which the digestive vacuole integrity 
remains intact despite 4hrs of incubation with the fluorescent probe 55. Higher 
concentrations lead to disruption of the food vacuole, in turn leading to parasite death. 
Thus probe 55 is an efficient substitute for the probes like 36a, 36b, 48a and further 
enables live cell imaging. 
      
 





























Fig. 17 – Live-cell imaging studies on P.falciparum using probe 55 
 
3.5   Macrophage study – 
Chloroquine is also used as an anti-inflammatory agent for the treatment of 
rheumatoid arthritis48,49,50. Its lysosomotropic property decreases the production of the 
pro-inflammatory cytokines IFN-γ, tumour necrosis factor-alpha (TNF-α), 
interleukin-6 (IL-6) in LPS- or phyto-hemagglutininstimulated peripheral blood 
mononuclear cells and the augmented LPS-induced expression of TNF- α, IL-1 α, IL-
1β and IL-6 in monocytic and microglial cells. The chloroquine probe 48a was 

























Time = 3hr 
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microscopy and flow cytometry techniques. It was confirmed that the probe exhibits 
lysosomotropic property by accumulating in the lysosomal compartments within 
macrophages in turn exerting their anti-inflammatory or pro-inflammatory effects. 
However the artesunate based probe 51 does not show specific localization in the 
lysosomes. Fig. 18, 19 and 20 show a comparision between flow cytometry (shown in 
four quadrant window) and confocal microscopy (10x magnification) for increasing 
concentration of probes. The four quadrants represent the distribution of cells extreme 
left bottom (unstained cells and live), extreme left top (dead cells stained by 
Propidium iodide (PI)), extreme right bottom (live cells stained with probe), extreme 
right top (semi-live and dead cells co-staining with propidium iodide and probes).  
              
 
     
Fig. 18 – Flow cytometry with confocal microscopy data for probe 48a 
Phase Probe 
PI Merge 





Fig. 19 – Flow cytometry with confocal microscopy data for probe 51 
 
 
Fig. 20 – Flow cytometry with confocal microscopy data for coumarin 34 
Thus the crude working concentrations for probe 48a and probe 51 which lies 
between 100 and 500µM. This concentration range shows staining of a maximum no 
of cells with minimal cell death. Three concentrations 50, 100 and 250µM were 
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confirms that coumarin-4-acetic acid 34 on its own does not stain macrophages at 
5nM, 5µM and 100µM concentrations, higher concentrations were not considered in 
the study. The graphical representation of flow cytometry results are shown below. 
Fig. 21 shows that the chloroquine probe 48a gives maximum staining of cells with 
minimal cell death (as measured by propidium iodide (PI) stain) at 100µM. Above 
100µM, the effect of DMSO along with the probe leads to higher cell death along 
with higher staining. Upon comparision with the coumarin fluorescent dye (34) alone 
for staining of macrophages, it was observed that probe 34 does not selectively stain 
macrophages and at concentrations above 100µM leads to cell death. This confirms 
that the staining of cells is primarily due to the chloroquine component of probe 48a. 
It also concludes that the probe has lysosomotropic properties like the parent drug 
chloroquine. The staining of cells is also observed at 100µM for artesunate probe 51 
but the results of the confocal imaging show interesting differences between probes 
48a and 51.  
 





















CQ-CM (+) PI (+)





Fig. 22 – Comparision of graphical Flow Cytometry results 34 
Upon observing macrophages incubated with the chloroquine probe 48a under 
standard conditions and at 60x magnification 2.5 optical zoom (Fig. 23), it was clear 
that the probe localizes within lysosomal compartment of the macrophages 
(confirmed against Lyso-Tracker red stain). This further double confirms the 
lysosomotropic nature of the probe thus confirming its action is similar to the parent   
molecule chloroquine diphosphate 4. In comparision, macrophages incubated with 
probe 51 did not show specific staining of lysosomal compartments of the 
macrophages, thus confirming the non-specific cell staining nature of artesunate or 
artesunate based probes. This also conforms that artesunate has multiple pathways of 
interaction within cells as hypothesized by Meschnick, Posner, Haynes and co-
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Fig. 23 – Confocal microscopy results of chloroquine probe 48a vs lyso tracker red. 
 
    
 
 





50µM  Probe 48a 100µM Probe 48a 250µM Probe 48a
Phase Probe 51
Lyso tracker Merge






3.6   NCI 60 Cancer Cell Line studies51,52 – 
3.6.1 Single dose study results on artesunate probe (51) – The chart below shows 60 
cancer cell lines and the effect of probe 51 on the growth of the cancer cells. The 
above results show the inhibitory effects on the majority of cancer cell lines, which 
can be further interpreted for its mode of action via the five dose studies results 
summarized in Fig. 26 and 28. 
3.6.2 Single and five dose study results on artesunate probe (51) – 
It can be concluded from the graphs summarized in Fig. 26 and 27 that artesunate 
probe 51 is potent against majority of cancer cell lines at concentrations of 10-8M to 
10-4M as compared against the standard cell line growth. Mean graph data compares 
growth inhibition “GI50” (drug concentration resulting in a 50% reduction in the net 
protein increase (as measured by SRB staining) in control cells during the drug 
incubation) ; total growth inhibition “TGI” (drug concentration resulting in total 
growth inhibition) and lethal concentration “LC50” (drug concentration resulting in a 
Standard Conditions Used
50,00,000 cells/well in glass bottom well
Incubate with probe 23a for 1hr
Incubate with Lysotracker for 1hr.
Lysotracker conc. fixed at 60nM.
Probe 48a Conc    - 100µM
Confocal Objective – 60X (Water)






50,00,000 cells/well in glass bottom well
Incubate with probe 27 for 1hr
Incubate with Lysotracker for 1hr.
Lysotracker conc. fixed at 60nM.
Probe 48a Conc    - 100µM
Confocal Objective – 60X (Water)
Phase Probe 51
MergeLyso Tracker Red
Fig. 25 – Localization studies results of chloroquine probe 48a (left) 
and artesunate probe 51 (right) vs lyso tracker red. 
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50% reduction in the measured protein at the end of the drug treatment as compared 
to that at the beginning indicating a net loss of cells). As observed from Fig. 27 and 
28, artesunate probe 51 inhibits the proliferation of majority of cancer cell lines at  
10-5 M mean concentration but does not lead to net loss of cells or cell death in the 
concentration range of 10-8 to 10-4 M. The above results confirms to the study of 
effects of artemisinins on cancer cell lines conducted by Woerdenbag et.al69. The 
above probe would be a useful tool to understand the modes of action within cancer 
cells  
 
Fig. 26 – NCI 60 cancer cell line data for artesunate probe 51 (Single Dose Data). 
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Fig. 27 – NCI 60 Cancer Cell Line data for Artesunate probe 51 (Five Dose Data). 




Fig. 28 – NCI 60 artesunate probe 51 (Mean Graph Data). 
 
3.6.3 Comparision of mean graph data of Probe 51 with Artesunate  – 
A comparision of five dose data with artesunate parent molecule shows that the 
artesunate probe 51 maintains the same efficacy as the parent molecule respite the 
attachment of the fluorescent molecule. Supporting data is enclosed in Appendix 3. 
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3.6.4 Single dose study results on chloroquine probe (48a) – The data in Fig. 30 
below shows that chloroquine probe (48a) has little toxic or inhibitory effect on 
majority of cancer cell lines at the single dose concentration of 10-5M. 
 
Fig. 30 – NCI 60 cancer cell line data for chloroquine probe 48a (Single Dose Data). 
 
3.6.5 Five dose study results on chloroquine probe (48a) – However the mean 5-dose 
data enclosed below in Fig. 31 and 32 showed some interesting results. As in Fig. 31, 
the chloroquine probe (48a) shows growth inhibition (GI50) of cell lines at 10-5M 
concentration but total growth inhibition of cell lines is only observed above 10-4M 
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concentrations, which conforms to a number of reports on use of chloroquine as an 
anti-cancer agent53.  
 
Fig. 31 – NCI 60 cancer cell line data for chloroquine probe 48a (mean graph). 
 
      
Fig. 32 – NCI 60 cancer cell line data for chloroquine probe 48a (5- Dose Data). 







Fig. 32 – NCI 60 cancer cell line data for chloroquine probe 48a (5- Dose Data). 
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3.6.6 Comparision of mean graph data of probe (48a) with parent molecule  – 
A comparision of five dose data with chloroquine parent molecule shows that the 
chloroquine probe (48a) maintains the same efficacy as the parent molecule respite 
the attachment of the fluorescent molecule as shown in Fig.33 (Supporting data 
Appendix 3).  
  
    
        
Fig. 33 – Comparision of mean graph data for Probe (48a) vs Chloroquine. 
Thus the above probes can also be used for understanding the modes of action of the 
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Thus I have synthesized chloroquine based probes 36b, 48a and artesunate based 
probes 51 with applications into malaria diagnostic, cancer bio-imaging study and 
other auto-immune diseases. Probe 36b as seen from the results (section 3.4) was able 
to clearly distinguish between chloroquine sensitive and chloroquine resistant strain of 
P.falciparum and coupled with its steadfast thermal stability (section 3.3.2) has 
established a robust diagnostic tool, fulfilling WHOs requirements for an fast, robust 
and effective diagnostic tool for malaria. Probe 48a (section 3.5) expands the 
applications of chloroquine probes for bio-imaging studies of auto-immune diseases. 
It was able to establish the lysosomotropic nature of the drug due to its localization 
within lysosomal compartment within the mammalian cell lines. Ultimately probe 48a 
(sections 3.6.3, 3.6.4) encompasses bio-imaging of cancer cell lines showing 
characteristics similar to the parent chloroquine diphosphate molecule. Probe 51 has 
also shown diverse applications from bio-imaging of auto-immune diseases (section 
3.5) to extremely high potency within cancer cell lines (sections 3.6.1, 3.6.2). It still 
needs to be evaluated for its activity within artemisinin resistant P.falciparum 
parasites.  
However probe 36b and 48a cannot be effectively used for in-vitro live cell imaging 
studies due to the detrimental effects of blue laser radiation. This is where chloroquine 
based probes (55, 83, 86, 92) have provided an advantage (section 3.4) due to sample 
& probe friendly green laser radiation and the high extinction coefficient of 
Borondipyrromethane (BODIPY). The chloroquine-bodipy probe 55 has show 
excellent resilience under green laser radiation while maintaining the efficacy and 
lysosomotropic properties of the parent drug molecule.  
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Although artesunate based probe 51 shows excellent anti-cancer activity, it has severe 
limitations due to its inherent poor hydrolytic stability and thermal stability (section 
2.3.4). Hence it was difficult to ascertain whether the fluorescent tag would sustain 
enzymatic cleavage within the cells. This limitation was overcome by the artelinic 
based probes (57, 83, 86, 98 and 100) which has shown excellent short term thermal 
resilience (appendix A1). However, long term stability (12months) of these probes, 
along with their biological activity is under study. All of the click probes (58-64, 87-
90) have show excellent short term thermal stability (4days), they still need to be 
evaluated for their ability to undergo click reaction in-situ in the cell. Further the final 
click product needs to be evaluated for its ease of separation and binding ability on its 
target for immunological study. Overall I have established the molecular tool for bio-
imaging and diagnostic application in malaria, cancer and mammalian cell lines. They 
have provided a clear picture of the mode of action of the drugs confirming with the 
hypothesis of lysosomotropic mode of action presented by many researchers in past 
papers27-30, 53-57. 
FUTURE WORK 
We have already observed the selective efflux of chloroquine probes from 
chloroquine resistant P.falciparum strains cultured in lab. The limitations of the 
chromophore have been surmounted by synthesis of superior BODIPY and TAMRA 
based probes (83, 86, 92, 95, 98, 100). Rising healthcare costs61 and increasing cases 
of cancer worldwide62 have stimulated focus of researchers on personalized medicine 
with the promise of effective and individualized healthcare where drugs would be 
administered as per individual patient responses. However this field which evaluates 
genetic data of individuals to address the right drug treatment is based on probabilistic 
model, is highly labor intensive and expensive63. 
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Fig. 34 – Healthcare costs (left) and Cancer incidences worldwide (right). 
The concept of fluorescent drug probe as addressed in my thesis for malaria and 
cancer can be expanded to include other diseases, giving rise to the field of 
“Medicinal Probes”.  
In comparision with the pharmacogenomics approach, medicinal probes could lead to 
a more direct method for visualization of individual drug response analysis using 
existing technology and instrumentation. Thus the future of drug probes lies into 
1) In-vitro live cell imaging capable probes (68-70) for malaria, cancer and other 
diseases. 
2)  In-vivo probes58 (71) for the study of mode of drug action within animal 
models. 
3) Tagging anti-cancer (72), anti-viral (73) and other drugs59 with probes with  
possible applications into bio-imaging or diagnostic studies. 
4) Copper free click chemistry probes (74, 75).60 for In-Vivo applications. 
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All chemicals were purchased from the Sigma-Aldrich Chemical Co. or Alfa Aesar 
and were used without further purification, unless indicated otherwise. Experiments 
were conducted at ambient temperature, unless noted otherwise. Analytical thin layer 
chromatography (TLC) was performed using a Merck 60 F254 pre-coated silica gel 
plate. Subsequent to elution, plates were visualized using UV radiation (254 nm). 
Further visualization was possible by staining with a Ninhydrin, Ceric ammonium 
molybdate (CAM) or Potassium permanganate (KMnO4) or 2,4-Dinitrophenol (2,4-
DNP) solutions. Silica gel 60 (230–400 mesh ASTM) was used for flash column 
chromatography. All the yields noted are for 96% purity of the compounds as 
analyzed by 1H, 13C NMR spectra (enclosed in Appendix A.2), LCMS for purity for 
biotesting submission (enclosed in Appendix A.4), IR and HRMS. Infrared spectra 
was recorded on a Bio-Rad FTS 165 FTIR spectrometer. 1H and 13C NMR spectra 
were recorded on a Brücker AMX 300 or 500MHz spectrometer. The NMR samples 
were prepared in a CDCl3, DMSO-d6 or MeOD-d4 solution. Chemical shifts are 
reported as δ in units of parts per million (ppm), calibrated based on the different 
solvents used (CDCl3 s 7.26; DMSO-d6 m 2.50; MeOD-d4 d 3.31).Multiplicities are 
given as: s (singlet); d (doublet); t (triplet) or m (multiplets), b (broad) and sex 
(sextet). Coupling constants (J) are represented in Hz. Purity and Thermal stability 
results were recorded on Shimadzu LC-IT-TOF spectrometer. High Resolution Mass 
Spectroscopy was recorded for new molecules using Finnigan LCQ mass 
spectrometer. Pre-calibrated weighing balance (for weighing samples for thermal 
stability studies), oven (maintained at 37oC) and freezer (maintained at -20oC) were 
used for thermal stability studies which were established using the ICH guidelines. 
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5.1   Synthesis scheme35-41  
5.1.1 General experimental procedure for the synthesis of N-(7-Chloro-4-quinolyl)-
1,n-diaminoalkanes (27a, 27b)  
A mixture of 4,7-dichloroquinoline (26) (3.0gms, 15.2 mmol, 1equiv.) and 
ethylenediamine (30) (4.55 gms, 75.7 mmol, 5 equiv) was heated to 110 °C for 6 h 
under inert atmosphere and then cooled to room temperature. Aqueous NaOH 
(0.61gms, 15.2 mmol, 1equiv,(1N soln., in 10mL)) was then added and the mixture 
was extracted with CH2Cl2. The organic layers were washed with water (50mL), brine 
(25mL), dried over anhydrous Na2SO4, and evaporated under reduced pressure to get 
N-(7-Chloro-4-quinolyl)-1,n-diaminoalkanes. 
 
N-(7-Chloro-4-quinolyl)-1,2-diaminoethane (27a) - Following the above procedure 
the compound was obtained as pale-yellow crystals with 86% yield. This was used 
without further purification.  Rf (1:9 MeOH: CH2Cl2+0.1%TEA) = 0.09. IR (KBr)/ 
cm-1 – 3248, 2916, 1581. 1H NMR (500MHz, MeOD) δ 8.35(1H, d, -N=CH-, 
J=9.45Hz), 8.04(1H, d, Ar-CH, J=9.45Hz), 7.76(1H, d, Ar-H, J=2.5Hz), 7.38(1H, dd, 
Ar-H, J=2Hz 6.95Hz), 6.56(1H, d, Ar-H, J = 5.7Hz), 3.45(2H, t, -NH-CH2-,J = 
6.3Hz),  2.93(2H, t, -NH2-CH2-, J = 6.3Hz) ; 13C NMR (500 MHz, MeOD) δ 152.6, 
152.4, 149.7, 136.4, 127.6, 126.1, 124.2, 118.8, 99.7, 50.3, 44.2 .MS(ES+): m/z (%): 
222.1 [M+H]+. 
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N-(7-Chloro-4-quinolyl)-1,4-diaminobutane (27b) – Employing the procedure 80% 
yield of pale-yellow crystals was obtained. Rf (1:9 MeOH: CH2Cl2+0.1%TEA) = 
0.03. IR (KBr)/cm-1 – 3255, 2932, 1582. 1H NMR(500MHz, MeOD) δ 8.34(1H, d, -
N=CH-, J=9.45Hz), 8.10(1H, d, Ar-CH, J=9. 5Hz), 7.77(1H, d, Ar-H, J=2.5Hz), 
7.39(1H, dd, Ar-H, J=2.5Hz,6.3Hz), 6.52(1H, d, Ar-H, J = 5.7Hz), 3.38(2H, t, -NH-
CH2-,J = 7.6Hz), 2.71(2H, t, -NH2-CH2-, J = 6.9Hz), 1.78(2H, m, -NH-CH2-CH2-),  
1.62(2H, m, -NH2-CH2-CH2-); 13C NMR (500 MHz, MeOD) δ 152.7, 152.4, 149.7, 
136.2, 127.6, 125.8, 124.3, 118.8, 99.6, 43.9, 42.3, 31.3, 26.8. MS (ES+): m/z (%): 
250.1 [M+H]+. 
5.1.2 General experimental procedure for the synthesis of 2-(7-chloroquinolin-4-
ylamino)ethanol and 4-(7-chloroquinolin-4-ylamino)butan-1-ol (76a, 76b)65 
A mixture of 4,7-dichloroquinoline (26) (4.0gms, 20.2mmol, 1equiv.), 1-
aminobutanol (24.71gms, 403.9 mmol, 20equiv) and TEA (0.62gms, 6.06 mmol, 0.3 
equiv.) was heated to 130 °C for 12-14 h under inert atmosphere and then cooled to 
room temperature. Water was added and the mixture was extracted with CH2Cl2. The 
organic layers were washed with water (50mL), brine (25mL), dried over anhydrous 
Na2SO4, and evaporated under reduced pressure to get 2-(7-chloroquinolin-4-
ylamino)ethanol. The compound was directly used without purification. 
 
2-(7-chloroquinolin-4-ylamino)ethanol (76a) – Yields – 80%, Rf (15% 
MeOH:CH2Cl2) = 0.25 . 1H NMR(500MHz, MeOD) δ 8.35(1H, d, -N=CH-, 
J=9.45Hz), 8.05(1H, d, Ar-CH, J=9.45Hz), 7.39(1H, dd, Ar-H, J=2Hz, 6.9Hz), 
7.78(1H, d, Ar-H, J=2.5Hz), 6.57(1H, d, Ar-H, J = 5.7Hz), 3.84(2H, t, -OH-CH2-, J = 
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5.7Hz),  3.50(2H, t, -NH2-CH2-, J = 5.7Hz);  13C NMR(500 MHz, MeOD) δ 152.9, 
152.4, 149.7, 136.4, 127.6, 126.0, 124.2, 118.8, 111.6, 99.7, 60.8, 46.3. MS (ES+): 
m/z (%): 222.8 [M]+. 
 
4-(7-chloroquinolin-4-ylamino)butan-1-ol (76b) – Yields – 100%, Rf (15% 
MeOH:CH2Cl2) = 0.2 . 1H NMR(500MHz, MeOD) δ 8.32(1H, d, -N=CH-, J=9.45Hz), 
8.07(1H, d, Ar-CH, J=9. 5Hz), 7.76(1H, d, Ar-H, J=2.5Hz), 7.36(1H, dd, Ar-H, 
J=2.5Hz, 11.5Hz), 6.49(1H, d, Ar-H, J = 5.7Hz), 3.34-3.65(4H, t, -OH-CH2-, -NH-
CH2-),  1.58-1.85(4H, m, -NH2-CH2-CH2-CH2-CH2-OH); 13C NMR(500 MHz, 
MeOD) δ 152.7, 152.4, 149.7, 136.3, 133.5, 131.8, 127.6, 125.9, 124.3, 120.3, 118.8, 
25.9, 99.6, 62.6, 43.9, 31.1. MS (ES+): m/z (%): 251.14 [M+H]+. HRMS(ES+) – 
obsvd. – 251.0953   ; calc. - 251.0946. 
5.1.3 General experimental procedure for the synthesis of 2-(7-chloroquinolin-4-yl 
amino)ethylmethanesulfonate, 4-(7-chloroquinolin-4-ylamino)butylmethanesulfonate 
(77a, 77b)65 
A mixture of 2-(7-chloroquinolin-4-ylamino)ethanol (76a) (1.0gms, 4.5 mmol, 1 
equiv.) in 13ml of pyridine is stirred for 30min. Then MsCl (1.54gm, 13.5mmol, 
3equiv) in 3ml of pyridine is added at 0oC under inert atmosphere. The reaction 
mixture is stirred at this temperature for 1hr, then warmed to room temperature and 
stirred for 5hrs. After confirmation with TLC, the mixture is transfered to a bigger 
round bottom flask kept at 0oC and about 5-10ml of 25% Ammonia solution is added 
slowly with stirring till solution turns basic. Water was added and the mixture till 
precipitation was observed. The mixture was extracted with CH2Cl2. The organic 
layers were washed with water (25mL), brine (15mL), dried over anhydrous Na2SO4, 
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and evaporated under reduced pressure till thick slurry is obtained. To this slurry 20ml 
diethyl ether and about 40ml hexane is added to precipitate out the product. The 
precipitate is separated from the solution and then dried thoroughly under vacuum to 
get 2-(7-chloroquinolin-4-yl amino)ethylmethanesulfonate. 
 
2-(7-chloroquinolin-4-yl amino)ethylmethanesulfonate (77a) – Yields-91%, Rf (15% 
MeOH:CH2Cl2) = 0.4 . 1H NMR(500MHz, CDCl3) δ 8.53(1H, d, -N=CH-, J=9.45Hz), 
7.96(1H, d, Ar-CH, J=9.45Hz), 7.77(1H, d, Ar-H, J=2.5Hz), 7.39(1H, dd, Ar-H, 
J=2Hz, 6.9Hz), 4.59(2H, t, -OH-CH2-, J = 5.7Hz), 6.41(1H, d, Ar-H, J = 5.7Hz), 
3.48(2H, t, -NH2-CH2-, J = 5.7Hz)  3.08(3H, OSO2-CH3);  13C NMR(500 MHz, 
CDCl3) δ 151.36, 149.49, 148.53, 135.48, 128.29, 125.98, 121.38, 117.15, 98.94, 
66.84, 42.49, 37.81. MS (ES+): m/z (%): 301.1 [M+H]+.  
 
4-(7-chloroquinolin-4-ylamino)butylmethanesulfonate (77b) – Yields – 92%, Rf (15% 
MeOH: CH2Cl2) = 0.35 . IR (KBr)/cm-1 – 3421, 2935, 1610, 1541, 1352, 1575. 1H 
NMR(500MHz, CDCl3) δ 8.46(1H, d, -N=CH-, J=9.45Hz), 7.91(1H, d, Ar-CH, 
J=9.45Hz), 7.78(1H, d, Ar-H, J=2.5Hz), 7.33(1H, dd, Ar-H, J=2Hz, 6.3Hz), 6.39(1H, 
d, Ar-H, J = 5.7Hz), 5.61(1H, b, -NH-), 4.31(2H, t, -CH2-OSO2CH3, J = 5.7Hz), 
3.39(2H, t, -NH2-CH2-, J = 5.7Hz), 3.01(3H, OSO2-CH3), 1.68-1.91(4H, m, -NH2-
CH2-CH2-CH2-CH2-OH); 13C NMR(500 MHz, CDCl3) δ 151.7, 150.9, 136.0, 128.5, 
126.2, 122.3, 117.7, 99.6, 70.1, 43.3, 38.2, 27.6, 25.5. MS(ES+): m/z (%): 329.1 
[M+H]+. HRMS (ES+) – observed – 329.0735   ; calculated. - 329.0721.  
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5.1.4a General experimental procedure for the synthesis of N-(7-chloro-4-quinolyl)-
N′,N′-diethyl-1,(n)-diaminoalkanes (Structures 29a,29b) and N-(7-chloro-4-quinolyl)-
N′-ethyl-1,n-diaminoalkanes (Structures 28a, 28b) 
To a solution of N-(7-chloro-4-quinolyl)-1,2-diaminoethane (27a) (1.0 g, 4.5 mmol, 1 
equiv.) in anhydrous DMF (10mL) was added Cs2CO3 (4.41 gms, 13.5 mmol, 3 
equiv). The solution was stirred at 25 °C for 0.5 h and ethyl bromide (0.49g, 4.5 
mmol, 1 equiv.) (diluted in 10mL anhydrous DMF) was added dropwise for 2hrs and 
then the reaction mixture is stirred at 25 °C for 24 h. DMF was removed in vacuum. 
The residue was dissolved in CH2Cl2, washed with water (10mL), brine (10mL) dried 
over anhydrous Na2SO4, and the organic extracts were removed under reduced 
pressure. Flash chromatography (2%-8% MeOH in CH2Cl2+0.1% TEA) allowed 
isolation of 0.21 g (16.8% yield) of N-(7-chloro-4-quinolyl)-N′,N′-diethyl-1,2-
diaminoethane (29a) and 0.38 g (33.7% yield) of N-(7-chloro-4-quinolyl)- N′-ethyl-
1,2-diaminoethane (28a) as pale-yellow crystals. 
5.1.4b Alternate general experimental procedure for the synthesis of N-(7-chloro-4-
quinolyl)-N′-ethyl-1,n-diaminoalkanes (Structures 28a,28b)  
To a mixture of 2-(7-chloroquinolin-4-yl amino)ethylmethanesulfonate (77a) 
(1.2gms, 4mmol, 1equiv.) in THF: MeOH (5:2) is added 2M ethylamine solution in 
THF (26.97gms (30mL), 598mmol, 150 equiv.). The solution is heated to reflux under 
inert atmosphere for 12-16hrs. After confirmation with TLC, the solution is cooled 
down. The product is isolated by removing the solvent under vacuum and further 
column with 10% MeOH in CH2Cl2 + 0.1% TEA. The diethyl amine by product is 
thus avoided and the yields are quantitative.   
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N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diaminoethane (28a) – Yields – 34% (as per 
procedure 4.1.4a) ; 90% (as per procedure 4.1.4b),  Rf (1:9 MeOH:CH2Cl2 +0.1% 
TEA) = 0.23 . IR (KBr)/cm-1 – 3271, 2963, 2847, 1582. 1H NMR(500MHz, MeOD) δ 
8.37(1H, d, -N=CH-, J=5.7Hz), 8.10(1H, d, Ar-H, J=8.8Hz), 7.78(1H, d, Ar-H, J 
=2.6Hz), 7.41(1H, dd, Ar-H, J=2.5Hz, 6.3Hz), 6.56(1H, d, Ar-H, J =5.7Hz), 3.51(2H, 
t, -NH-CH2-, J = 6.3Hz), 2.96(2H, t, -NH-CH2-, J = 7.0Hz), 2.72(2H, q, -CH2-CH3-, 
J=7.0Hz), 1.16(3H, t, -CH2-CH3-, J=7.6Hz); 13C NMR(500 MHz, MeOD) δ 152.8, 
152.5, 149.7, 136.4, 127.6, 126.1, 124.3, 118.8, 99.7, 44.7, 43.2, 14.6. MS (ES+): m/z 
(%): 250.1 [M+H]+.  
 
N-(7-Chloro-4-quinolyl)-N′-ethyl-1,4-diaminobutane (28b) – Following procedure 
described above and purification by flash chromatography (2%-8% MeOH in 
CH2Cl2+0.1% TEA) gave 18% yield( procedure 4.1.4a), 80% yield( procedure 4.1.4b) 
of pale-yellow crystals. Rf (1:9 MeOH:CH2Cl2+0.1%TEA) = 0.2 IR (KBr)/cm-1 – 
3289, 3279, 1582. 1H NMR(500MHz, MeOD) δ 8.34(1H, d, -N=CH-, J=5.1Hz), 
8.09(1H, d, Ar-H, J=8.9Hz), 7.77(1H, d, Ar-H, J=2.0Hz), 7.39(1H, dd, Ar-H, 
J=2.0Hz, 6.9Hz), 6.52(1H, d, Ar-H, J = 5.7Hz), 3.30(2H, t, -NH-CH2-, J = 7.0Hz), 
2.67(4H, q, -CH2-CH3-, J = 7.0Hz), 1.79(2H, m, -NH-CH2-CH2-), 1.66(2H, m, -NH2-
CH2-CH2-), 1.13(3H, t, -CH2-CH3 -, J=7.0Hz); 13C NMR(500 MHz, MeOD) δ 152.7, 
152.4, 149.7, 136.2, 127.6, 125.9, 124.3, 118.8, 99.6, 49.9, 44.5, 43.8, 27.9, 27.2, 
14.5. MS (ES+): m/z (%): 278.1 [M+H]+. 
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N-(7-Chloro-4-quinolyl)-N′,N′-diethyl-1,2-diaminoethane (29a) – Rf (1:9 
MeOH:CH2Cl2 +0.1 %TEA) = 0.3 . IR(KBr)/cm-1 – 3233, 2970, 1582. 1H 
NMR(500MHz, MeOD) δ  8.37(1H, d, -N=CH-, J=5.1Hz), 8.04(1H, d, Ar-H, 
J=8.8Hz), 7.78(1H, d, Ar-H, J=2.0Hz), 7.41(1H, dd, Ar-H, J=2.0Hz, 6.9Hz), 6.55(1H, 
d, Ar-H, J = 5.1Hz), 3.48(2H, m, -NH-CH2-, J = 6.3Hz), 2.82(2H, m, -N-CH2-, J = 
7.0Hz), 2.67(4H, q, -CH2-CH3-, J=7Hz), 1.34(6H, t, -CH2-CH3-, J=7.6Hz); 13C 
NMR(500 MHz, MeOD) δ 152.6, 152.5, 149.7, 136.4, 127.7, 126.1, 124.1, 118.8, 
99.7, 49.5, 48.1, 41.4, 11.6. MS (ES+): m/z (%): 278.1 [M+H]+. LCMS Purity -96%. 
Rt = 0.75 min. Eluent system – 0% - 100% ACN/H2O+0.1% TFA 
 
N-(7-Chloro-4-quinolyl)-N′,N′-diethyl-1,4-diaminobutane (29b) – Following 
procedure described and purification by flash chromatography (2%-8% MeOH in 
CH2Cl2+0.1% TEA) gave 23% yield of pale-yellow crystals. Rf 
(MeOH:CH2Cl2+0.1%TEA) = 0.36. IR (KBr)/cm-1 – 3217, 2932, 2793, 1582. 1H 
NMR(500MHz, CDCl3) δ 8.51(1H, d, -N=CH-, J=5.7Hz), 7.94(1H, d, Ar-H, 
J=2.0Hz), 7.73(1H, d, Ar-H, J=9.5Hz), 7.34(1H, dd, Ar-H, J=2.0Hz, 6.9Hz), 6.38(1H, 
d, Ar-H, J = 5.1Hz), 6.00(1H, s, -NH-), 3.30(2H, t, -NH-CH2-, J = 6.3Hz), 2.60(4H, q, 
-CH2-CH3-, J = 7.0Hz), 2.53(2H, m, -N-CH2-), 1.84(2H, m, -NH-CH2-CH2-), 
1.69(2H, m, -NH2-CH2-CH2-), 1.05(6H, t, -CH2-CH3-, J=7.0Hz); 13C NMR(500 MHz, 
CDCl3) 152.7, 152.4, 149.7, 136.3, 127.6, 125.9, 124.3, 118.8, 99.7, 53.5, 47.8, 43.8, 
27.5, 24.9, 11.1. MS (ES+): m/z (%): 306.1 [M+H]+. LCMS Purity -98%. Rt = 
10.3min. Eluent system – 0% - 100% ACN/H2O+0.1% TFA 
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5.1.5 General Experimental procedure for the synthesis of Monoboc diamine (31, 38)   
To a solution of the ethylene diamine (30) (3gms, 49.9mmol, 5equiv.) in (100ml) dry 
CH2Cl2 was added dropwise dilute solution (100ml of dry CH2Cl2) of boc anhydride 
(2.18gms, 9.99mmol, 1equiv.) under rigorous stirring in ice-water over a period of 
40min under Ar atmosphere. The reaction is stirred for 12hrs and checked using TLC 
(9:1 CH2Cl2: MeOH +0.1% TEA). The reaction mixture is diluted with 50ml of 
dichloromethane and then washed with distilled water (100mL) and brine (50mL) to 
remove un-reacted diamine in a separating funnel. The CH2Cl2 layer is dried over 
Na2SO4 and concentrated in vacuum. The product can be directly used without further 
purification as viscous oil in 90% yield which was stored under Ar atmosphere at 
20oC.   
 
1-(tert-Butyloxycarbonyl) ethyldiamine (31) – The residue can be used directly after 
work-up with 31 as viscous oil in 90% yield which was stored under Ar atmosphere at 
20oC. Rf (9:1 CH2Cl2: MeOH +0.1% TEA) = 0.22 .  IR (NaCl)/ cm-1 – 3364, 2878, 
2932, 1697, 1528, 1172.7. 1H NMR(500MHz, CDCl3) δ 4.92(1H, b, -NH-), 3.20(2H, 
t, J= 5Hz, -CH2-NH-), 2.79(2H, t, J= 5Hz, -CH2-NH-), 1.43(9H, s, -C(CH3)3). 13C 
NMR(500 MHz, CDCl3) δ 156.2, 79.5, 43.3, 41.8, 28.3. MS(ES+): m/z (%): 160.8 
[M+H]+, 201 [M+CH3CN]+. 
 
 
N-Boc-1,8-diamino-3,6-dioxaoctane (38) – Following procedure product was 
obtained in 90% yield. Rf (9:1 CH2Cl2: MeOH +0.1% TEA) = 0.26 . IR(NaCl)/ cm-1 – 
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3372, 2924, 2870, 1697. 1528, 1173, 1111. 1H NMR(500MHz, CDCl3) δ 3.50(2H, d, 
J=28Hz, -CH2-NHBoc), 3.42(2H, t, J=9.6Hz, J=9.0Hz m, -O-CH2CH2-O-), 3.19(2H, 
t, J= 8.3Hz, -O-CH2CH2-), 2.76(2H, t, J= 8.5Hz, -CH2-NH2-), 1.32(9H, s, -C(CH3)3).  
13C NMR(500 MHz, CDCl3) δ 155.8, 78.8, 72.9, 69.9, 41.6, 40.0, 28.3. MS(ES+): m/z 
(%): 249 [M+H]+. 
5.1.6 General experimental procedure for the synthesis of N-(tert-
Butyloxycarbonyl)amino ethyl-2-bromoacetamide (33,40) 
Bromoacetic acid (44mgs, 0.31mmol, 1equiv) was added to a single neck flask 
containing freshly distilled CH2Cl2 (10 ml). The solution was cooled to -10oC using 
ice-methanol mixture. Di-isopropylethylamine (DIPEA) (81mgs, 0.62 mmol, 2equiv) 
was added immediately at this followed by addition (2-(7-Aza-1H-benztriazole-1-yl))-
1,1,3,3,-tetramethylammonium hexafluorophosphate (HATU) (142mgs, 0.37mmol, 
1.2equiv) and 3H-[1,2,3]triazolo[4,5-b] pyridine-3-ol (HOAt) (51mgs, 0.37mmol, 1.2 
equiv) and after 10min of stirring 1-(tert-Butyloxycarbonyl) ethyldiamine (31) (50 
mgs, 0.31mmol, 1equiv) is added in the sequence respectively. The reaction is 
maintained under Ar atmosphere and -10oC till the addition of the above components 
is complete. The reaction is cooled to room temperature gradually and stirring is 
continued at room temperature till TLC shows the product spot. The product was 
isolated by washing the reaction mixture with water and separating the 
dichloromethane layer. Dichloromethane was distilled under vacuum and the residue 
was purified by flash chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) in 80% 
yield. 
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N-(tert-Butyloxycarbonyl) aminoethyl-2-bromoacetamide (33) – Employing the 
procedure the residue was purified by flash chromatography (2% - 4% MeOH 
inCHCl3+ 0.1% TEA) in 80% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.33 . 1H 
NMR(500MHz, CDCl3) δ 7.09(1H, b, -NH-CO-), 4.88(1H, b, -NH(Boc)), 3.86(2H, s, 
-CO-CH2-Br), 3.40(2H, m, -NH-CH2-), 3.29(2H, m, -CH2-NH(Boc)), 1.45(9H, s, -
C(CH3)3). 13C NMR(500 MHz, CDCl3) δ  166.3, 157.8, 79.9, 41.6, 39.8, 28.9, 28.4. 




Employing the above procedure and purification by flash chromatography in 90% 
yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.36 . 1H NMR(500MHz, CDCl3) δ 1.43(9H, 
s, -C(CH3)3), 2.79(2H, s, -CH2-NHCO-), 3.52(10H, m , -NH(Boc)-CH2-CH2-O-CH2-
CH2-O-CH2-), 4.04(1H, b, -CO-CH2-Br), 4.98(1H, b, -NH(Boc)) 6.94(1H, b, -NH-
CO-) .  13C NMR(500 MHz, CDCl3) δ 165.7, 155.9, 79.9, 70.3, 70.2,  70.1, 69.4, 40.3, 
39.9, 29.0, 28.4. MS (ES+): m/z (%): 390.9 [M+Na]+. 
 
5.1.7 General experimental procedure for the synthesis of (7-Coumarin-
acetamide)aminoethyl -2-bromoacetamide (35) 
N-(tert-Butyloxycarbonyl)aminoethyl-2-bromoacetamide (33) (60mgs, 0.21mmol, 1 
equiv.) was dried overnight under vacuum and then placed under Ar atmosphere. 1ml 
of freshly distilled dichloromethane was added to above reactant. The reaction 
mixture was cooled to 4oC using Ice bath and then Trifluoroacetic acid (TFA) 
(243mgs, 2.13mmol, 10equiv.) was added immediately under Ar atmosphere using a 
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syringe. The reaction was checked after 1hr by TLC (9:1 CH2Cl2:MeOH + 0.1% 
TEA) for absence of starting material. After confirmation by TLC the reaction 
mixture is distilled under vacuum at 16-18oC to remove excess TFA and CH2Cl2. The 
residue is flushed with argon to release the vacuum and then 2-4ml of freshly distilled 
dry ether is added to observe precipitation of the TFA salt of the amine. If no 
precipitation is observed then the ether is removed under vacuum and after flushing 
the TFA salt with Argon the residue is kept under vacuum line for 10min. The residue 
is placed under Ar atmosphere using a balloon and then 10-12ml of Dichloromethane 
(dry freshly distilled) was added. The reaction mixture is cooled to -10oC using ice-
methanol mixture. Di-isopropylethylamine (82.7 mgs, 0.64 mmol, 3equiv) was added 
immediately at this followed by addition of 7-Dimethyl coumarin-4-acetic acid (34) 
(53mgs, 0.21mmol, 1equiv), HATU (98mgs, 0.26 mmol, 1.2equiv) and HOAt (35 
mgs, 0.26mmol, 1.2equiv) is added in the sequence respectively. The reaction is 
maintained under Ar atmosphere and -10oC till the addition of the above components 
is complete. The reaction is cooled to room temperature gradually and stirring is 
continued at room temperature till TLC shows the product spot. The product was 
isolated by washing the reaction mixture with water and separating the 
dichloromethane layer. Dichloromethane was distilled under vacuum and the residue 
was purified by flash chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) in 60% 
yield.  
 
(7-Coumarin-acetamide) aminoethyl-2-bromoacetamide (35) – Yield – 70% 
Compound is unstable and is to be used directly for next step. Hence characterization 
was not done on this molecule. MS (ES+): m/z (%): 431.96 [M+Na]+ 




(7-Coumarin-acetamide) aminoethoxyethoxyethyl-2-bromoacetamide (41) - was 
Obtained following the above process and flash chromatography in 90% yield. 
Compound is unstable and is to be used directly for next step. Hence characterization 
was not done on this molecule.  
 
5.1.8 General experimental procedure for the synthesis of Chloroquine based probes 
(36a, 36b, 42) - N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diaminoethane (28a) (16.8mgs, 
0.07mmol, 1equiv.) and freshly dried K2CO3 (18.6mgs, 0.135mmol, 2equiv.) were 
stirred together in a single neck flask under Ar atmosphere in 2-3ml of dry 
Acetonitrile. (7-Coumarin-acetamide)aminoethyl-2-bromo acetamide (35) (27.6mgs, 
0.07mmol, 1equiv.) was added directly in dried powder form to the above reaction 
mixture at 4oC (Ice water). Ice Water is removed after the addition is done and the 
reaction is stirred at room temperature for 12hrs. After confirmation of formation of 
product by TLC (9:1 CH2Cl2:MeOH+0.1%TEA). The reaction mixture is columned 
through celite and 50ml of Acetonitrile is added to extract the product from the 
column. Acetonitrile is distilled under vacuum and the residue is purified by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA).  
 
2-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)-N-(2-(2-(7-(dimethylamino)-
2-oxo-2H-chromen-4yl) acetamido) ethyl) acetamide (36a) –  Following the above 
procedure and purification by flash chromatography (2% - 4% MeOH in 
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CHCl3+0.1%TEA) the compound was obtained in 65% yield.  Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.41. IR(KBr)/cm-1 – 3364, 2924, 2855, 1659, 1613, 
1582. 1H NMR(500MHz, MeOD) δ 8.29(1H, d, Chlor-CH-, J= 5.7Hz), 8.02(1H, d, 
Chlor-CH-, J= 9.5Hz), 7.71(1H, s, Cl-C=CH- , J= 2Hz), 7.41(1H, d, Cou-CH-, 
J=8.9Hz), 7.23(1H, dd, Ar-H, J=2.0Hz, 8.9Hz), 6.55(1H, dd, Ar-H , J=2.6Hz, 9.5Hz), 
6.44(1H, d, Cou-CH, J= 5.7Hz), 0.95(3H, t, -CH2-CH3, J= 7.0Hz), 6.23(1H, d, -
N=CH=CH-, J= 2.5Hz), 5.98(1H, s, Cou-CH), 3.38(6H, m, -NHCO-CH2-
N(CH2CH3), -CH2-NH-, -CH2-NHCO), 3.30(2H, t, -CH2-NHCO-, J= 5.7Hz), 
3.08(2H, s, Coum-CH2-CONH-), 2.94(6H, s, -N(CH3)2), 2.70(2H, t, -N-CH2-, J= 
6.3Hz), 2.53(2H, q, -CH2CH3, J= 7.6Hz); 13C NMR(500 MHz, MeOD) δ 174.9, 172.1, 
164.1, 157.0, 153.0, 152.6, 151.5, 148.6, 136.7, 126.9, 126.7, 126.1, 124.8, 118.6, 
110.5, 110.3, 109.8, 99.5, 98.5, 59.0, 53.7, 50.3, 41.2, 40.1, 40.0, 14.5, 12.2. MS 
(ES+): m/z (%): 579.3 [M+H]+. HRMS (ES+) m/z calc. - 579.2497, observed – 
579.2500. LCMS Purity - 96%. Rt = 8.33-8.47 min. Eluent system – 10% 
ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
 
2-((4-(7-chloroquinolin-4-ylamino)butyl)(ethyl)amino)-N-(2-(2-(7-(dimethylamino)-
2-oxo-2H-chromen-4-yl)acetamido) ethyl) acetamide (36b) – Following the above 
procedure and purification by flash chromatography (2% -6% MeOH in 
CHCl3+0.1%TEA) the compound was obtained in 70% yield. Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.44. IR (NaCl) / cm-1 – 3333, 2932, 2862, 1713, 1613, 
1582, 1528. 1H NMR(500MHz, MeOD) δ 8.29 (1H, d, Ar-H, J= 5.8 Hz), 7.99 (1H, 
Ar-H, d, J= 9.1 Hz), 7.71 (1H, d, Ar-H, J= 2.0 Hz), 7.42 (1H, d, Ar-H, J= 8.8 Hz), 
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7.25 (1H, dd, Ar-H, J= 2.0 Hz, 8.8 Hz), 6.55 (1H, dd, Ar-H, J=2.6 Hz, 9.1 Hz), 6.43 
(1H, d, Ar-H, J= 5.8 Hz), 6.34 (1H, d, Ar-H, J= 2.3Hz), 5.98 (1H, s), 3.63 (2H, s), 
3.38-3.40 (4H, m), 3.21 (2H, m), 2.97 (8H, bs), 2.41 (2H , t, J= 7.0 Hz), 2.49 (2H, q, 
J= 7.0 Hz), 1.62-1.74 (2H, -CH2-CH2-CH2-CH2-N((CH2CH3)(CH2)), m), 1.52-1.57 
(2H, m, NH-CH2-CH2-CH2-),  0.87 (3H, t, -CH2CH3, J= 6.4 Hz),; 13C NMR(500 
MHz, MeOD) δ 175.2, 171.5, 164.2, 157.1, 154.6, 152.2, 149.4, 152.7, 136.2, 127.3, 
126.8, 125.8, 124.5, 118.7, 110.5, 110.3, 109.7, 99.6, 98.6, 58.7, 55.7, 50.0, 47.4, 
44.0, 40.2, 40.1, 40.0, 27.1, 26.2, 12.1. MS (ES+): m/z (%): 608.3 [M+2H]+. HRMS 
(ES+)  m/z calculated 608.2848, observed - 608.2847. LCMS Purity -96%. Rt = 8.73-
8.89 min. Eluent system – 10% ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
 
N-(1-(7-chloroquinolin-4-ylamino)-3-ethyl-5-oxo-9,12-dioxa-3,6-diazatetradecan-14-
yl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamide (42) – Following the 
above procedure and purification by flash chromatography (2% - 4% MeOH in 
CHCl3+0.1%TEA) the compound was obtained in 60% yield. Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.56. IR (NaCl)/cm-1 – 3279, 3071, 2924, 2862, 1713, 
1613, 1528. 1H NMR (500MHz, CDCl3) δ 8.29(2H, d, Chlor-CH-, d, , J= 5.7Hz), 
7.76(1H, d, Chlor-CH-, J= 1.9Hz), 7.52(2H, dd, Cou-CH-, Cl-C-CH2-, J= 1.9Hz, 
8.8Hz), 6.68(1H, dd, Cou-CH-, Cou-CH-, J= 2.5Hz, 2.6Hz), 6.41(1H, d, -N=CH=CH- 
, J= 2.5Hz), 6.01(1H, s, Cou-CH-), 3.55(16H, m), 3.25 (2H, s, Coum-CH2-CONH-), 
3.03(6H, s, -N(CH3)2), 2.89 (2H, t, -N-CH2-, J= 6.3Hz), 2.69 (2H, q, -CH2CH3, J= 
7.0Hz), 1.07 (3H, t, -CH2CH3, J= 7.5Hz); 13C NMR(500 MHz, CDCl3) δ 172.0, 168.3, 
162.1, 155.9, 153.1, 126.8, 125.8, 124.1, 116.1, 109.5, 109.3, 108.3, 98.0, 97.9, 70.2, 
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69.6, 69.5, 57.2, 52.2, 48.7, 42.1, 40.1, 39.5, 39.1, 12.0. MS(ES+): m/z (%): 667.4 
[M]+. HRMS (ES+)  m/z calc. - 668.3100, obsvd. – 668.3098. LCMS Purity -96%. Rt 
= 8.83-8.87 min. Eluent system– 10% ACN/H2O+0.1%TFA – 100% 
ACN/H2O+0.1%TFA. 
5.1.9 General procedure for synthesis of tert-butyl 2-(2-((2-(7-chloroquinolin-4-
ylamino)ethyl)(ethyl)amino)acetamido)ethylcarbamate and tert-butyl 2-(2-((4-(7-
chloroquinolin-4-ylamino)butyl)(ethyl)amino)acetamido)ethylcarbamate (54a, 54b) 
N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diaminoethane (28a) (100mgs, 0.4mmol, 
1equiv.) and freshly dried K2CO3 (166mgs, 1.2mmol, 3equiv.) were stirred together in 
a single neck flask under Ar atmosphere in 2-3ml of dry Acetonitrile. N-(tert-
Butyloxycarbonyl) aminoethyl-2-bromoacetamide (33) (170mgs, 0.6mmol, 1.5equiv.) 
was added as Acetonitrile solution to the above reaction mixture at 0oC (Ice water). 
Ice Water is removed after the addition is done and the reaction is stirred at room 
temperature for 12hrs. After confirmation of formation of product by TLC (10% 
MeOH: CH2Cl2). The reaction mixture is columned through celite and 50ml of 
Acetonitrile is added to extract the product from the column. Acetonitrile is distilled 
under vacuum and the residue is purified by flash chromatography (6% -8% MeOH in 
CHCl3+0.1%TEA). 
 
tert-butyl 2-(2-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)acetamido) ethyl 
carbamate (54a) –  
Yields – 70%. Rf (1:9 MeOH:CH2Cl2+0.1%TEA) = 0.45. IR (KBr)/cm-1 – 3306, 
2972, 2939, 1694, 1668, 1613, 1541, 1451. 1H NMR(500MHz, MeOD)  δ 8.37(1H, d, 
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-N=CH-, J=5.7Hz), 8.31(1H, d, Ar-H, J=8.9Hz), 7.80(1H, d, Ar-H, J=2.0Hz), 
7.51(1H, dd, Ar-H, J=2.0Hz, 6.9Hz ), 6.63(1H, d, Ar-H, J = 5.7Hz), 2.87-3.25 (10H, 
m, -CH2-NH(Boc), NH-CH2-, -NH2-CH2-CH2-, -NH-CH2-CH2-, -CO-CH2-N), 
2.67(4H, q, -CH2-CH3-, J = 7.0Hz), 1.40(9H, s, -C(CH3)3),1.07(3H, t, -CH2-CH3 -, 
J=7.0Hz); 13C NMR(500 MHz, MeOD) δ 174.6, 154.1, 149.9, 147.0, 137.8, 126.9, 
125.5, 125.1, 118.3, 99.7, 80.1, 58.4, 53.6, 50.0, 42.6, 40.9, 40.6, 28.8, 12.2. MS 




carbamate (54b) – 
Yields – 70%, Rf (1:9 MeOH:CH2Cl2+0.1%TEA) = 0.4. IR (KBr)/cm-1 – 3306, 2957, 
2924, 2853, 1695, 1676, 1655, 1582, 1533, 1451. 1H NMR(500MHz, CDCl3) δ 
8.39(1H, d, -N=CH-),7.85(1H, d, Ar-CH, J=9.45Hz), 7.57(1H, d, Ar-H, J=2.5Hz), 
7.22(1H, dd, Ar-H, J=2Hz,8.2Hz), 6.29(1H, d, Ar-H, J = 5.7Hz), 3.22-3.32 (6H, m), 
2.98(2H, s, -CO-CH2-N-), 2.47(4H, m), 1.50-1.73(4H, m, -NH2-CH2-CH2-CH2-CH2-
OH), 1.37(9H, s, -C(CH3)3), 0.96(3H, t, -CH2-CH3 -, J=7.0Hz),  ; 13C NMR(500 MHz, 
CDCl3) δ 173.3, 157.2, 152.1, 150.9, 149.3, 135.4, 128.5, 125.6, 122.6, 117.9, 99.3, 
80.1, 58.4, 55.1, 54.0, 49.7, 43.7, 41.1, 39.9, 29.0, 28.9, 26.9, 25.7, 12.6. MS(ES+): 
m/z (%): 478.1 [M+H]+. HRMS (ES+) – observed – 478.2585; calculated. - 478.2579. 
5.1.10 General procedure for synthesis of tert-butyl 3-((2-(7-chloroquinolin-4-
ylamino)ethyl)(ethyl)amino)propylcarbamate(80) - N-(7-Chloro-4-quinolyl)-N′-ethyl-
1,2-diaminoethane (28a) (400mgs, 1.6mmol, 1equiv.) and TEA (242mgs, 3.2mmol, 
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2.0equiv.) and tert-butyl 3-bromopropylcarbamate (649mgs, 2.4mmol, 1.5equiv.)  
were stirred together in a single neck flask under Ar atmosphere in 3ml of dry DMF. 
The reaction mixture was heated to 80oC under inert atmosphere for 12-16hrs. After 
confirmation of formation of product by TLC (10% MeOH:CH2Cl2), DMF was 
removed by evaporation under vacuum. The residue was purified by flash 
chromatography (6% -8% MeOH in CHCl3+0.1%TEA). 
 
tert-butyl3-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)propylcarbamate(80)– 
Yields – 85%, Rf – 0.55 (10% MeOH:CH2Cl2), IR (KBr)/cm-1 – 3421.72, 2974.23, 
2973.59, 2756.28, 2738.92, 2490.1, 1689.64, 1614.42, 1581.63. 1H NMR(500MHz, 
MeOD) δ 8.28(1H, d, -N=CH-, J=5.1Hz), 7.99(1H, d, Ar-H, J=8.9Hz), 7.69(1H, d, 
Ar-H, J=2.0Hz), 7.32(1H, dd, Ar-H, J=2.0Hz,11.6Hz), 6.47(1H, d, Ar-H, J = 5.7Hz), 
3.50(1H, m), 2.50-3.24(10H, m, -CH2-CH3-, J = 7.0Hz), 1.53-1.60(2H, m), 1.31(9H, 
s, -C(CH3)3), 0.99(3H, t, -CH2-CH3 -, J=7.0Hz),; 13C NMR(500 MHz, MeOD) δ 
158.5, 152.9, 151.7, 148.8, 136.7, 127.0, 126.3, 124.3, 118.6, 99.8, 89.0, 79.9, 52.5, 
51.9, 41.5, 39.5, 28.8, 28.0, 11.7. MS (ES+): m/z (%): 407.1[M+H]+. HRMS (ES+) 
m/z calc. – 407.2222 , observed – 407.2225. 
5.1.11 General procedure for synthesis of (55 and 92) 
Tert-butyl 2-(2-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)acetamido) ethyl 
carbamate (54a) (100 mgs,  0.22 mmol, 1.0 equiv.) is added to flame dried single neck 
flask under argon containing dried 1mL dichloromethane. To this solution 
trifluoroacetic acid (634 mgs(414 µL), 5.6mmol, 25.0 equiv.) is added at 0oC and the 
reaction mixture is stirred till all the boc amine is converted to trifluoroacetate salt of 
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amine as per TLC. After confirmation by TLC, the solvent is removed under vacuum 
and vacuum is released under Ar atmosphere. Dry ether is added to precipitate the 
free amine. In case no precipitation is observed the solution is dried under vacuum for 
15min and then kept under argon. Fresh dried dichloromethane is added to the 
reaction mixture and then its cooled to -10oC. DIPEA (718 mgs(970µL), 5.6mmol,      
25equiv.) is added at -10oC followed by HATU (126mgs, 0.33mmol, 1.5equiv) and 
HOAt (45mgs, 0.33mmol, 1.5equiv) and finally BODIPY (84) (65 mgs, 0.22 mmol,  
1equiv) is added to the reaction mixture at -10oC. The reaction mixture is warmed to 
room temperature and stirred at this temperature for 12-16hrs. Upon confirmation by 
TLC the solvent is removed under vacuum and the crude is purified by column 




f][1,3,2]diazaborinin-4-ium-5-uide (55) – Following the above procedure and 
purification by flash chromatography (4% - 8% MeOH in CH2Cl2) the compound was 
obtained in 70% yield. Rf (1:9 MeOH:CH2Cl2) = 0.45. IR (KBr)/cm-1 – 3412, 2950, 
1608, 1448, 1383, 1252, 1136, 1084. 1H NMR (500MHz, MeOD) δ 8.33(1H, d, J= 
9Hz, Ar-H), 8.25(1H, d, J= 6.3Hz, Ar-H), 7.69(1H, d, J= 2Hz, Ar-H), 7.42 (1H, dd, J= 
2Hz, 6.9Hz, Ar-H), 7.26(1H, s, Ar-H), 6.90(1H, d, J= 4Hz, Ar-H), 6.58(1H, d, 
J=6.95Hz, Ar-H), 6.23(1H, s, Ar-H), 6.10(1H, s, Ar-H), 3.68-3.73(2H, m), 3.46(2H, t, 
J= 6.4Hz, NHCO-CH2-CH2-), 3.30-3.35(4H, m & s, N-CH2-CO-),  3.14-3.23(2H, m), 
2.82(2H, t, J= 6.3Hz, NHCO-CH2-CH2-), 2.59-2.66(4H, m, N-CH2-CH3-), 2.39(3H, s, 
BODIPY-CH3), 2.20(3H, s, BODIPY-CH3), 1.03(3H, t, J= 6.9Hz, N-CH2-CH3-); 13C 
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NMR (500MHz, MeOD) δ 175.2, 174.6, 161.2, 158.3, 155.1, 147.5, 145.7, 144.2, 
138.6, 136.4, 134.7, 129.5, 127.3, 125.7, 125.6, 123.3, 121.3, 117.7, 117.1, 99.6, 58.5, 
55.8, 53.4, 50.1, 43.8, 42.9, 40.6, 39.9, 35.5, 25.4, 18.0, 14.9, 13.2, 12.2, 11.3. MS 
(ES+): m/z (%): 624.25 [M+H]+. HRMS(ES+)  m/z calc. – 624.2837 , observed – 
624.2861. LCMS Purity -96%. Rt = 8.73-8.89 min. Eluent system – 10% 




4-ium-5-uide (92) – Following the above procedure and purification by flash 
chromatography (6% - 10% MeOH in CHCl3+0%TEA) the compound was obtained 
in 65% yield. Rf (1:9 MeOH: CH2Cl2) = 0.40. IR (KBr)/cm-1 – 2954, 2920, 2851, 
1608, 1465, 1251, 1136. 1H NMR(500MHz, MeOD) δ 8.32(1H, d, -N=CH-, 
J=6.3Hz), 8.14(1H, d, Ar-H, J=8.9Hz), 7.74(1H, d, Ar-H, J=2.0Hz), 7.45(1H, dd, Ar-
H, J=2.0Hz, J=6.9Hz), 7.27(1H, s, Ar-H), 6.94(1H, d, Ar-H, J = 4Hz), 6.59(1H, d, Ar-
H, J = 5.7Hz), 6.30(1H,d, Ar-H, J= 4Hz), 6.09(1H, s, Ar-H), 3.49(2H, t, J=6.3Hz), 
3.18-3.27 (4H, m), 2.60-2.78(6H,m), 2.43 (3H, s, BODIPY-CH3), 2.15 (3H, s, 
BODIPY-CH3), 1.74(2H, q, -CH2-CH3-, J=7.0Hz ), 1.08(3H, t, -CH2-CH3-, J=7.0Hz); 
13C NMR(500 MHz, MeOD) δ 174.9, 161.4, 158.3, 154.1, 149.3, 146, 145.8, 136.5, 
134.8, 129.5, 127.1, 125.6, 125.0, 124.9, 118.1, 117.3, 99.8, 83.6, 71.3, 55.8, 54.8, 
52.2, 51.7, 43.8, 41.3, 38.1, 35.6, 30.7, 27.1, 25.6, 18.0, 14.9, 13.2, 11.2, 11.1. MS 
(ES+): m/z (%): 581.23 [M+H]+. HRMS(ES+)  m/z calc. – 581.2778 , observed – 
581.2777.  LCMS Purity -96%. Rt = 11.9-12.2 min. Eluent system – 0% 
ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
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5.1.12 General experimental procedure for synthesis of (9H-fluoren-9-yl)methyl 3-
hydroxy propylcarbamate (44) 
 To a solution of the 3-amino propanol (43) (3.76gms, 50.0mmol, 1equiv.) in (10ml) 
dry CH2Cl2 was added dropwise Fmoc-OSu (8.92gms, 50.0 mmol, 1equiv.) under 
rigorous stirring in ice-water over a period of 40min under Ar atmosphere. The 
reaction is stirred for 12hrs and checked using TLC (9:1 CH2Cl2: MeOH +0.1% 
TEA). The reaction mixture is diluted with 50ml of dichloromethane and then washed 
with distilled water (50mL) and brine water (25mL) to remove un-reacted amine in a 
separating funnel. The CH2Cl2 layer is dried over Na2SO4 and concentrated in vacuum 
to obtain viscous oil which is directly used for the next step without purification. The 
product is obtained as white solid (44) 70% yield. 
 
 
(9H-fluoren-9-yl)methyl 3-hydroxypropylcarbamate (44) - The product is obtained as 
white solid in 70% yield. Rf (1:9 MeOH:CH2Cl2+0.1%TEA) = 0.75. IR (KBr)/cm-1 – 
3327, 2947, 2885, 1692, 1543, 1445, 1267. 1H  (300MHz, CDCl3) δ  7.76(2H, d, Ar-
CH-, J= 4.6Hz), 7.59(2H, d, Ar-CH-, J= 4.6Hz), 7.40(2H, m, Ar-CH-, J= 7.4Hz), 
7.32(2H, m, Ar-CH-, J= 7.4Hz), 5.00(1H, b, -NH-), 4.44(2H, d, J= 6.6Hz), 4.22(1H, t, 
-CO2-CH2-CH-, J=6.6Hz), 3.65(2H, d, -CONH-CH2-, J= 5.4Hz), 3.36(2H,m, -CH2-
CH2-OH), 2.46(1H, b, -OH-), 1.70(2H, m, -CH2-CH2-OH); 13C (300 MHz, CDCl3) δ 
157.4, 143.9, 141.3, 127.7, 127.0, 125.0, 120.0, 66.7, 59.5, 47.3, 37.6, 32.6. MS 
(ES+): m/z (%): 297.9 [M]+,  320.18 [M+Na]+. 
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5.1.13 General experimental procedure for synthesis of (9H-fluoren-9-yl)methyl 3-
oxo propyl carbamate (45) 
(9H-fluoren-9-yl) methyl 3-oxopropylcarbamate (44) (0.10gms, 0.34 mmol, 1equiv.) 
was added to 2 ml of freshly distilled dry dichloromethane and Dess-Martin 
periodinane (0.357gms, 0.84mmol, 2.5equiv.) was added to the reaction mixture at 
room temperature. The reaction mixture is monitored by TLC till the presence of 
aldehyde is observed. After reaction is complete the reaction mixture is filtered and 
the dichloromethane extract is vacuum distilled to obtain a white solid which is 
further purified by flash chromatography (25% - 50% EtOAc in Hexane) in 70% 
yield. 
 
(9H-fluoren-9-yl)methyl 3-oxopropylcarbamate (45) – Rf (1:1 EtOAc:Hex) = 0.88.  
IR (KBr)/cm-1 – 3329, 2957, 2925, 2855, 1725, 1691, 1543, 1269. 1H (300MHz, 
CDCl3) δ 9.81(1H, s, -CHO-), 7.76(2H, d, Ar-CH-, J= 7.4Hz), 7.56(2H, d, Ar-CH-, J= 
7.5Hz), 7.40(2H, t, Ar-CH-, J= 7.4Hz), 7.31(2H, t, Ar-CH-, J= 7.4Hz), 5.51(1H, b, -
NH-), 4.39(2H, d, J= 6.9Hz), 4.20(1H, t, -O-CH2-CH-, J=6.9Hz), 3.49(2H, m, -CH2-
CHO, J= 3.4Hz), 2.75(2H, t, -CONH-CH2-, J=3.4Hz),  ;13C (300 MHz, CDCl3) δ 
201.2, 156.3, 143.9, 141.3, 127.7, 127.0, 125.0, 120.0, 66.7, 47.3, 44.1, 34.5. MS 
(ES+): m/z (%): 296.00 [M+H]+. 
5.1.14 General experimental procedure for synthesis of (9H-fluoren-9-yl) methyl 3-
((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl) amino) propylcarbamate (46a. 46b)  
(9H-fluoren-9-yl)methyl 3-oxopropylcarbamate (45) (0.036gms, 0.12 mmol, 2 equiv.) 
was dried under vacuum overnight and then about 5-8ml of freshly distilled dried 
CH2Cl2 was added to the single neck flask kept under Ar atmosphere. N-(7-Chloro-4-
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quinolyl)-N′-ethyl-1,2-diamino ethane (28a) (0.015gms, 0.06 mmol, 1 equiv.) was 
added to the reaction mixture. The reaction mixture was cooled to 4oC (using Ice 
Water) and then NaBH(OAc)3 (0.025gms, 0.12 mmol, 2.0) was weighed quickly and 
added immediately to the reaction mixture. The reaction mixture was stirred at room 
temperature till TLC shows formation of product. After the reaction is complete 
distilled water is added to the reaction mixture and then 4-5ml of saturated NaHCO3 is 
added to the reaction mixture. The mixture is then extracted with ethyl acetate and the 
ethyl acetate extract is vacuum distilled and further the residue is purified by flash 
chromatography (2% - 4% MeOH in CHCl3+ 0.1% TEA) to obtain the product in 
(0.025) 70% yield.  
 
(9H-fluoren-9-yl) methyl 3-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl) amino) 
propylcarbamate (46a) – The residue is purified by flash chromatography (2% - 4% 
MeOH in CHCl3+ 0.1% TEA) to obtain the product in 70% yield. Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.35 . IR (KBr)/cm-1 – 3384, 2959, 2925, 1645, 1457, 
1378. 1H (500MHz, CDCl3) δ 8.51(1H, d, Ar-CH, J= 4.7Hz), 7.94(1H, d, Ar-CH, J= 
1.9Hz), 7.74(2H, d, Ar-CH, J= 7.6Hz), 7.69(1H, d, Ar-CH, J=8.9Hz),  7.54(2H, d, Ar-
CH, J= 7.6Hz), 7.38(2H, t, Ar-CH, J= 7.6Hz), 7.30(1H, dd, Ar-CH, J=2.6, 9.1Hz), 
7.27(2H, t, Ar-CH, J= 7.6Hz), 6.35(1H, d, Ar-CH, J=5.1Hz), 5.87(1H, b, -NH-Fmoc), 
5.14(1H, b, -NH-Chloroquine), 4.39(2H, d, -O-CH2-CH-, J= 6.9Hz), 4.17(1H, t, -O-
CH2-CH-, J=6.9Hz), 3.27(2H, m, -CH2-NH(Fmoc), J=5.7Hz), 2.79(2H, m, 
NCH2CH3-CH2-, J=5.7Hz), 2.59(2H, m, -CH2-NCH2CH3, J=7.6Hz), 2.56(2H, q, -
NCH2CH3, J=6.9Hz, 12.6Hz), 1.69(4H, m, -NH-CH2-CH2-NCH2CH3), 1.65 (2H, m, -
CONH-CH2CH2CH2-), 1.05(3H, t, -NCH2CH3, J=6.9Hz); 13C(500 MHz, CDCl3) δ 
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156.4, 152.0, 149.7, 149.1, 143.9, 141.3, 134.8, 128.7, 127.6, 127.0, 125.3, 124.9, 
121.3, 119.4, 117.4, 99.2, 66.4, 51.5, 50.8, 47.3, 46.8, 40.1, 39.5, 27.4, 11.7. MS 
(ES+): m/z (%): 529.2 [M]+. HRMS (ES+) m/z calc. - 529.2378, observed – 529.2377. 
 
(9H-fluoren-9-yl)methyl3-((4-(7-chloroquinolin-4-ylamino)butyl)(ethyl)amino)propyl  
carbamate (46b) – Following the above procedure using N-(7-Chloro-4-quinolyl)-N′-
ethyl-1,4-diaminobutane (28b) (0.015gms, 0.05 mmol, 1 equiv.)  and purification by 
flash chromatography (2% -6% MeOH in CHCl3+0.1%TEA) gave 77% yield. Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.26. IR (KBr)/cm-1 – 3384, 2958, 2924, 1645, 1564, 
1456, 1378. 1H (500MHz, CDCl3) δ 8.49(1H, d, Ar-CH, J= 5.1Hz), 7.94(1H, d, Ar-
CH, J= 1.9Hz), 7.74(2H, d, Ar-CH, J= 7.6Hz), 7.54(2H, d, Ar-CH, J= 7.6Hz), 
7.38(2H, t, Ar-CH, J= 7.6Hz), 7.30(1H, dd, Ar-CH, J=2.6, 9.1Hz), 7.27(2H, t, Ar-CH, 
J= 7.6Hz), 6.35(1H, d, Ar-CH, J=5.1Hz), 5.14(1H, b, -NH-Fmoc), 5.14(1H, b, -NH-
Chloroquine), 4.39(2H, d, -O-CH2-CH-, J= 5.7Hz), 4.17(1H, t, -O-CH2-CH-, 
J=6.9Hz), 3.26(2H, m, -CH2-NH(Fmoc), J= 5.7Hz), 2.62(2H, m, NCH2CH3-CH2- , 
J=5.7Hz), 2.56(2H, q, -NCH2CH3, J=6.9, 12,6Hz), 2.48(4H, m, -CH2-NCH2CH3), 
1.69(2H, m, -NH-CH2-CH2-N CH2CH3, J=6.3Hz), 1.65 (2H, m, -CONH-CH2CH2CH2-
), 1.05(3H, t, -NCH2CH3, J=6.9Hz); 13C (500 MHz, CDCl3) δ 156.4, 152.0, 149.8, 
149.1, 144.0, 141.3, 134.7, 128.7, 127.6, 127.0, 126.9, 125.0, 124.9, 121.1, 120.0, 
98.9, 66.4, 53.0, 52.4, 47.3, 46.2, 43.2, 40.8, 26.8, 26.5, 25.1, 11.5. MS (ES+): m/z 
(%): 557.3 [M]+. HRMS (ES+) m/z calc. - 557.2691, observed – 557.2691. 
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5.1.15 General experimental procedure for synthesis of N1-(2-(7-chloroquinolin-4-
ylamino)ethyl)-N1-ethylpropane-1,3-diamine (47a. 47b) 
(9H-fluoren-9-yl)methyl3-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)propyl  
carbamate (46a) (0.025gms, 0.01 mmol, 1 equiv.) was dried overnight under vacuum 
and then about 1-2ml of freshly distilled dry CH2Cl2 was added to the single neck 
flask under Ar atmosphere. The reaction mixture was cooled to 4oC (using Ice water) 
and then piperidine (0.035gms, 0.05 mmol, 5 equiv.) was added to the reaction 
mixture immediately with vigorous stirring. The reaction mixture was stirred at room 
temperature till TLC shows product formation. After completion of the reaction as 
observed by TLC the reaction mixture was distilled under vacuum to remove 
piperidine and then the compound is purified by flash chromatography 15-25% 
MeOH in CHCl3+0.1%TEA to get 13mgs of crude product. 
 
N1-(2-(7-chloroquinolin-4-ylamino)ethyl)-N1-ethylpropane-1,3-diamine (47a) - The 
crude is purified by flash chromatography 15-25% MeOH in CHCl3+0.1%TEA to get 
85% yield of crude product. 1H (500MHz, CDCl3) δ 8.51(1H, d, Ar-CH, J= 5.7Hz), 
7.92(1H, d, Ar-CH, J= 1.9Hz), 7.74(1H, d, Ar-CH, J= 8.8Hz), 7.35(1H, dd, Ar-CH, 
J=2.6, 9.1Hz), 6.35(1H, d, Ar-CH, J=5.1Hz), 3.30(2H, m, NCH2CH3-CH2-, J=5.7Hz), 
2.82(2H, t, -CH2-N(CH2 CH3), J=4.4Hz), 2.60(6H, m, -NCH2CH3, -NH-CH2-CH2-
NCH2CH3, -CH2-NH2), 1.65 (2H, m, -CONH-CH2CH2CH2-), 1.07(3H, t, -NCH2CH3, 
J=6.9Hz);  13C (500 MHz, CDCl3) δ 152.0, 150.0, 149.0, 134.8, 128.6, 125.3, 121.4, 
117.5, 99.2, 51.3, 51.2, 47.1, 40.5, 40.1, 30.0, 11.8. MS(ES+): m/z (%): 307.6 
[M+H]+. 




N1-(3-aminopropyl)-N4-(7-chloroquinolin-4-yl)-N1-ethylbutane-1,4-diamine (47b) – 
Following the above procedure using (9H-fluoren-9-yl)methyl3-((4-(7-
chloroquinolin-4-ylamino) butyl)(ethyl)amino)propylcarbamate (46b) (0.025gms, 
0.01 mmol, 1 equiv.) and the compound was obtained in 80% crude product. 1H 
(500MHz, CDCl3) δ 8.51(1H, d, Ar-CH, J= 5.7Hz), 7.92(1H, d, Ar-CH, J= 1.9Hz), 
7.74(1H, d, Ar-CH, J= 8.8Hz), 7.35(1H, dd, Ar-CH, J=2.6, 9.1Hz), 6.35(1H, d, Ar-
CH, J=5.1Hz), 3.30(2H, m, NCH2CH3-CH2-, J=5.7Hz), 2.82(2H, t, -CH2-N(CH2 
CH3), J=4.4Hz), 2.60(6H, m, -NCH2CH3, -NH-CH2-CH2-NCH2CH3, -CH2-NH2), 1.65 
(2H, m, -CONH-CH2CH2CH2-), 1.07(3H, t, -NCH2CH3, J=6.9Hz);  13C (500 MHz, 
CDCl3) δ 152.0, 150.0, 149.0, 134.8, 128.6, 125.3, 121.4, 117.5, 99.2, 51.3, 51.2, 
47.1, 40.5, 40.1, 30.0, 11.8. MS (ES+): m/z (%): 335.2 [M]+. HRMS (ES+) m/z calc. - 
335.1997, observed – 335.1988. 
 
5.1.16 General experimental procedure for synthesis of N-(3-((2-(7-chloroquinolin-4-
ylamino)ethyl)(ethyl)amino)propyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-
yl)acetamide tert-butyl (48a, 48b) 
7-Dimethyl coumarin-4-acetic acid (34) (8mgs, 0.03mmol, 1equiv.) was placed under 
Ar atmosphere and then 10-12ml of Dichloromethane (dry freshly distilled) was 
added. The reaction mixture is cooled to -10oC using ice-methanol mixture. DIPEA 
(10.0 mgs, 0.06 mmol, 2 equiv) was added immediately followed by addition of N1-
(2-(7-chloroquinolin-4-ylamino)ethyl)-N1-ethylpropane-1,3-diamine(47a)(10mgs, 
0.03mmol, 1 equiv), HATU (15 mgs, 0.04 mmol, 1.2 equiv) and HOAt (8 mgs, 0.04 
Page 82 of 219 
 
 
mmol, 1.2 equiv) is added in the sequence respectively. The reaction is maintained 
under Ar atmosphere and -10oC till the addition of the above components is complete. 
The reaction is cooled to room temperature gradually and stirring is continued at room 
temperature till TLC shows the product spot. The product was isolated by washing the 
reaction mixture with water (10mL) and separating the dichloromethane layer. 
Dichloromethane was distilled under vacuum and the residue was purified by flash 
chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) to obtain (7mgs) 40% yield 
of pure product.  
 
N-(3-((2-(7-chloroquinolin-4-ylamino)ethyl)(ethyl)amino)propyl)-2-(7-(dimethyl 
amino)-2-oxo-2H-chromen-4-yl)acetamide tert-butyl (48a) – The residue was purified 
by flash chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) to obtain 60% yield 
of pure product. Rf (1:9 MeOH: CH2Cl2+0.1%TEA) = 0.36. IR (KBr)/cm-1 - 3383, 
2957, 2925, 1646, 1565, 1455, 1377.   1H (500MHz, CDCl3) δ 8.33(1H, d, Chlor-CH, 
J= 5.7Hz), 8.06(1H, d, Chlor-CH, J= 9.5Hz), 7.75(1H, s, Cl-C=CH-), 7.53(1H, d, 
Cou-CH-, J=8.9Hz), 7.35(1H, dd, Cl-CH, J=2.0Hz, 8.9Hz), 6.68(1H, d, -N=C=CH-, 
J= 2.5Hz), 6.45(1H, dd, (CH3)2N-CH2-CH2- , J=2.6Hz, 9.5Hz), 6.03(1H, s, Cou-CH), 
3.30(2H, s, Coum-CH2-CONH-), 2.94(6H, s, -N(CH3)2), 2.4-2.8(6H, m), 1.72(2H, q, -
CH2CH3, J= 7.6Hz), 0.95(3H, t, -CH2CH3, J= 7.6Hz),; 13C (500 MHz, MeOD) δ 
171.1, 164.2, 157.2, 154.8,  152.8, 152.8, 152.7, 152.2, 149.4, 136.4, 127.4, 126.9, 
125.9, 124.4, 118.7, 110.5, 110.3, 109.7, 99.7, 98.7, 54.0, 51.9, 47.6, 43.8, 40.2, 39.1, 
24.9, 11.2. MS (ES+): m/z - 536.3 [M+H]+.  HRMS (ES+) m/z - calc. 536.2445, 
obsvd. – 536.2441. LCMS Purity -96%. Rt = 8.55-8.73 min. Eluent system – 10% 
ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 





amino)-2-oxo-2H-chromen-4-yl)acetamide (48b) – Following the above procedure 
and purification by flash chromatography (2% - 4% MeOH in CHCl3+0.1%TEA) the 
compound was obtained in 65% yield. Rf (1:9 MeOH:CH2Cl2+0.1%TEA) = 0.30. IR 
(KBr)/cm-1 - 3384, 2958, 2924, 1645, 1564, 1456, 1378. 1H (500MHz, MeOD) δ 
8.33(1H, d, Chlor-CH, J= 5.7Hz), 8.06(1H, d, Chlor-CH, J= 9.5Hz), 7.75(1H, s, Cl-
C=CH-), 7.53(1H, d, Cou-CH-, J=8.9Hz), 7.35(1H, dd, Cl-CH-, J=2.0Hz, 8.9Hz), 
6.68(1H, d, -N=C=CH-, J= 2.5Hz), 6.45(1H, dd, (CH3)2N-CH2-CH2- , J=2.6Hz, 
9.5Hz), 6.03(1H, s, Cou-CH), 3.30(2H, s, Coum-CH2-CONH-), 2.94(6H, s, -
N(CH3)2), 2.4-2.8(6H, m), 1.72(6H, m), 0.95(3H, t, -CH2CH3, J= 7.6Hz); 13C (500 
MHz, MeOD) δ 171.1, 164.2, 157.2, 154.8,  152.8, 152.8, 152.7, 152.2, 149.4, 136.4, 
127.4, 126.9, 125.9, 124.4, 118.7, 110.5, 110.3, 109.7, 99.7, 98.7, 54.0, 51.9, 47.6, 
43.8, 40.2, 39.1, 27.7, 26.9, 24.9, 11.2, 9.9. MS (ES+): m/z - 564.3 [M+H]+. HRMS 
(ES+) m/z - calc. 564.2376, obsvd. – 564.2723. LCMS Purity -96%. Rt = 9.2-9.22 
min. Eluent system – 10% ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
5.1.17 General experimental procedure for synthesis of N-(2-(7-chloroquinolin-4-yl 
amino) ethyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamide (49a, 49b) 
N-(7-Chloro-4-quinolyl)-1,2-diaminoethane (27a) (30mgs, 0.12mmol, 1 equiv.) was 
added under Ar atmosphere and 2.5ml of anhydrous DMF was added to above 
reactant. The reaction mixture was cooled to 4oC using Ice bath and then 7-Dimethyl 
coumarin-4-acetic acid (34) (53 mgs, 0.21mmol, 1 equiv), DCC (27 mgs, 0.13 mmol, 
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1.1 equiv) and HOBt (18 mgs, 0.13 mmol, 1.2 equiv) was added in the sequence 
respectively. The reaction is maintained under Ar atmosphere and 4oC till the addition 
of the above components is complete. The reaction is cooled to room temperature 
gradually and stirring is continued at room temperature till TLC shows the product 
spot. The product was isolated by removing the reaction mixture under vacuum and 
then the residue was extracted with cold ethyl acetate separating the dicyclohexylurea 
by-product which precipitates out from the cold ethyl acetate. Ethyl acetate filtrate 
was distilled under vacuum and the residue was purified by flash chromatography 
(2% - 4% MeOH inCHCl3+ 0.1% TEA) (41mgs) (49a) 67% yield. 
 
N-(2-(7-chloroquinolin-4-ylamino)ethyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-
4-yl)acetamide (49a) – The residue was purified by flash chromatography (2% - 4% 
MeOH inCHCl3+ 0.1% TEA) to get 55% yield of product. Rf (1:9 
MeOH:CH2Cl2+0.1%TEA) = 0.21. IR (KBr)/cm-1 – 3325, 3063, 2924. 1705, 1620, 
1535. 1H (500MHz, DMSO-d6) δ 8.39(1H, d, Chlor-CH, J= 5.7Hz), 8.36(1H, b, -
NHCO-), 8.06(1H, d, Chlor-CH, J= 8.8Hz), 7.78(1H, d, Cl-C=CH- , J= 2.5Hz), 
7.46(1H, b, Chlor-NH-),   7.42(1H, dd, Cl-C-CH-, J=2.0Hz, 8.9Hz), 7.40(1H, s, Cl-C-
CH-), 6.56(1H, dd, (CH3)2N-C-CH- , J=2.5Hz, 8.8Hz),, 6.43(1H, d, Cou-CH, J= 
2.5Hz), 6.41(1H, d, -N=C=CH-, J= 7.0Hz), 6.02(1H, s, Cou-CH), 3.62(2H, s, Cou-
CH2), 3.37-3.41(4H, m, -NH-CH2-, -CH2-NHCO), 2.97(6H, s, N(CH3)2); 13C (500 
MHz, DMSO-d6) δ 168.7, 168.6, 160.6, 155.3, 152.5, 150.9, 150.8, 150.3, 147.1, 
134.1, 126.0, 125.7, 124.4, 124.0, 116.9, 109.6, 108.6, 108.0, 98.5, 97.2, 42.3, 40.0, 
37.5, 37.4. MS (ES+): m/z (%): 451.2 [M+H]+. HRMS (ES+) m/z calc. - 473.1351, 
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observed – 473.1361. LCMS Purity -96%. Rt = 8.8-8.99min. Eluent system – 10% 
ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
 
N-(4-(7-chloroquinolin-4-ylamino)butyl)-2-(7-(dimethyl amino)-2-oxo-2H-chromen-
4-yl)acetamide (49b) – Following the above procedure and purification by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was obtained 
in 60% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.20. IR (KBr)/cm-1 – 3487, 3363, 
2924, 2862, 1689, 1612, 1589, 1535. 1H (500MHz, DMSO-d6) δ  8.37(1H, d, Chlor-
CH, J= 5.7Hz), 8.26(1H, d, Chlor-CH, J= 9.5Hz), 8.18(1H, b, -NHCO-), 7.53(1H, d, 
Cou-CH-, J=8.9Hz), 7.77(1H, d, Cl-C=CH- , J= 2.0Hz), 7.43(1H, dd, Cl-C-CH-, 
J=2.0Hz, 8.9Hz), 7.30(1H, b, Chlor-NH-), 6.65(1H, dd, (CH3)2N-C-CH- , J=2.5Hz, 
8.8Hz), 6.53(1H, d, Cou-CH, J= 2.6Hz), 6.46(1H, d, -N=C=CH-, J= 5.1Hz), 5.99(1H, 
s, Cou-CH), 3.58(2H, s, Cou-CH2), 3.25(2H, t, -CH2-NHCO-, J= 7.0Hz), 3.13(2H, t, -
NH-CH2-, J= 7.0Hz), 2.97(6H, s, N(CH3)2), 1.62-1.68(2H, m, -CH2-CH2-), 1.50-
1.56(2H, m, -CH2-CH2-); 13C (500 MHz, DMSO-d6) δ 167.6, 160.6, 155.3, 152.7, 
151.3, 150.2, 148.7, 133.4, 127.2, 125.9, 124.1, 124.0, 117.3, 109.3, 108.9, 108.1, 
98.6, 97.4, 42.0, 38.4, 26.6, 25.1. MS (ES+): m/z (%): 479.2 [M+H]+. HRMS (ES+) 
m/z calc. - 479.1861, observed – 479.1858. LCMS Purity -96%. Rt = 9.69-9.73 min. 
Eluent system – 10% ACN/H2O+0.1%TFA – 100% ACN/H2O+0.1%TFA. 
5.1.18 General experimental procedure for the synthesis of tert-butyl 2-(2-(7-
(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)ethylcarbamate (50,52, 82, 85 ). 
1-(tert-Butyloxycarbonyl) ethyldiamine (31) (130mgs,   0.81mmol, 1equiv) was added 
to a single neck flask containing freshly distilled CH2Cl2 (10 mL). The solution was 
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cooled to -10oC using ice-methanol mixture. 7-Dimethyl coumarin-4-acetic acid (34) 
(200mgs, 0.81mmol, 1equiv) was added followed by di-isopropylethylamine (210 
mgs, 1.62mmol, 2equiv), HATU (370mgs, 0.97mmol, 1.2equiv) and HOAt (130 mgs, 
0.97mmol, 1.2equiv) in the sequence respectively. The reaction is maintained under 
Ar atmosphere and -10oC till the addition of the above components is complete. The 
reaction is cooled to room temperature gradually and stirring is continued at room 
temperature till TLC shows the product spot. The product was isolated by washing the 
reaction mixture with water and separating the dichloromethane layer. 
Dichloromethane was distilled under vacuum and the residue was purified by flash 
chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) in 60% yield. This method 
was primarily used to synthesize 50,52 and 85. In case of TAMRA (81) based 
intermediates the procedure enclosed below is followed. 6-TAMRA-COOH (81) (100 
mgs, 0.23 mmol, 1.0equiv) is added to flame dried single necked flask containing dry 
THF 5mL. The reaction mixture was cooled to -10oC and then ethylchloroformate (38 
mgs (33µL), 0.35 mmol, 1.5equiv) and TEA (35 mgs (48 µL), 0.35 mmol, 1.5equiv). 
The reaction mixture is stirred for 1hr at this temperature and then 1-(tert-
Butyloxycarbonyl) ethyldiamine (31) (56 mgs, 0.35mmol, 1.5equiv) is added in liquid 
form directly to the reaction mixture at -10oC. The reaction mixture is gradually 
cooled to room temperature and stirred for 16-18hrs. After confirmation with TLC, 
the solvent is removed under vacuum and then the crude is purified by column 
chromatography (10% -15% MeOH in CHCl3) to get (82). 
 
Page 87 of 219 
 
 
tert-butyl 2-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl) acetamido) ethyl 
carbamate (50) – Following the above procedure and purification by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was obtained 
in 60% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.48. (500MHz, CDCl3) 1H (500MHz, 
CDCl3) δ 7.46 (1H, d, J =9.5Hz, Coum-H), 6.6 (1H, dd, J = 2.5, 8.8Hz, Coum-H), 
6.48 (1H, d, J = 8.8Hz, Coum-H),  6.04 (1H, s, Coum-H), 4.89(1H, bs, -NH), 3.61 
(2H, s, -CH2-CO-), 3.33 (4H, m), 3.01 (6H, s,-N(CH3)2), 1.04 (9H, s, O=C-O-
C(CH3)3); 13C (500 MHz, CDCl3) δ 168.6, 161.7, 156.0, 153.1, 149.5, 125.6, 110.6, 
109.1, 108.4, 98.3, 79.8, 45.8, 41.3, 40.7, 40.1, 28.3. MS(ES+): m/z (%): 412.2   
[M+Na]+. HRMS(ES+) m/z calc. – 412.1867 , observed – 412.1857 . 
 
tert-butyl2-(2-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)ethoxy)ethyl 
carbamate (52) – Following the above procedure and purification by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was obtained 
in 99% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.30. 1H (500MHz, CDCl3) δ 7.46 
(1H, d, J =9.5Hz, Coum-H), 6.57 (1H, dd, J = 2.5, 8.8Hz, Coum-H), 6.44 (1H, d, J = 
8.8Hz, Coum-H), 6.03 (1H, s, Coum-H), 5.04(1H, br, -NH-), 3.5 (14H, m), 3.01 (6H, 
s,-N(CH3)2), 1.04 (9H, s, O=C-O-C(CH3)3),  13C(500 MHz, CDCl3) δ 168.6, 161.7, 
155.9, 155.8, 152.9, 149.9, 125.6, 110.1, 109.0, 98.1, 79.5, 70.2, 70.1, 69.5, 40.3, 
39.9, 39.5, 28.3. MS(ES+) m/z (%): 500.2 [M+Na]+. HRMS(ES+) m/z calc. – 
500.2381, obsvd. – 500.2375. 





6-ylcarboxamido)ethylcarbamate (82) – Following the above procedure and 
purification by flash chromatography (10% -15% MeOH in CHCl3+0.1%TEA) the 
compound was obtained in 70% yield. Rf (9:1 MeOH: CH2Cl2) = 0.30. IR(KBr)/ cm-1 
– 3421, 2922, 1647, 1597, 1491, 1366, 1348. 1H (500MHz, DMSO-d6) δ 8.69(1H, b,-
NH-), 8.05-8.14 (2H, m,Ar-H), 7.62 (1H, s, Ar-H), 6.84 (1H, b,-NH-), 6.5 (6H, s, Ar-
H), 3.04-3.21 (4H, m), 2.96 (12H, s,(-N(CH3)2)2), 1.29 (9H, s, O=C-O-C(CH3)3). 13C 
(500 MHz, DMSO-d6) δ 164.8, 155.6, 152.2, 129.2, 128.6, 97.8, 77.6, 28.1. MS (ES+) 
m/z (%): 573.1 [M+H]+. HRMS (ES+) m/z calc. – 573.2708, obsvd. – 573.2722 
 
3-(3-(2-(tert-butoxycarbonylamino)ethylamino)-3-oxopropyl)-5,5-difluoro-7,9-
dimethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-ium-5-uide (85) – 
Following the above procedure and purification by flash chromatography (6% -8% 
MeOH in CHCl3) the compound was obtained in 70% yield. Rf (50% EtAc:Hex) = 
0.50. IR(KBr)/cm-1 – 3422, 3395, 2972, 2916, 1695, 1653, 1523.  1H (500MHz, 
MeOD) δ 7.42(1H, s, N-C-CH-C-N+) , 7.00(1H, m, Ar-CH-), 6.32(1H, m, Ar-CH-),  
6.20(1H, s, Ar-CH-), 3.10-3.25(4H, t, NH-C-CH-CH-CO-, NH-CH2-CH2-NH(Boc),  
J=6.9), 2.61(2H, t, NH-C-CH2-CH-CO-, J=6.9Hz), 2.51 (3H, s, -CH3- ), 2.27 (3H, s, -
CH3- ), 1.42(9H, s, O-(CH3)3-); 13C (500 MHz, MeOD) δ 174.9, 161.3, 158.5, 145.8, 
136.5, 134.9, 129.6, 125.8, 121.3, 117.6, 99.9, 80.1, 40.9, 40.5, 36.1, 28.7, 25.6, 14.9, 
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11.2. MS (ES+) m/z (%): 457.11  [M+Na]+. HRMS (ES+) m/z calc.–457.2222, obsvd. 
– 457.2209. 
5.1.19 General experimental procedure for synthesis of Artemisinin based probes (51, 
53, 57, 83, 86, 98-100) Tert-butyl2-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl) 
acetamido) ethylcarbamate (50) (10mgs, 0.026mmol, 1equiv.) was dried overnight 
under vacuum and then placed under Ar atmosphere. 1ml of freshly distilled 
dichloromethane was added to above reactant. The reaction mixture was cooled to 
4oC using Ice bath and then Trifluoroacetic acid (TFA) (29mgs, 0.26mmol, 10equiv.) 
was added immediately under Ar atmosphere using a syringe. The reaction was 
checked after 1hr by TLC (9:1 CH2Cl2:MeOH + 0.1% TEA) for absence of boc 
product. After confirmation by TLC the reaction mixture is distilled under vacuum at 
16-18oC to remove excess TFA and CH2Cl2. The residue is flushed with argon to 
release the vacuum and then 2-4ml of freshly distilled ether is added to observe 
precipitation of the TFA salt of the amine. If no precipitation is observed then the 
ether is removed under vacuum and after flushing the TFA salt with Argon the residue 
is kept under vacuum line for 10min. The residue is placed under Ar atmosphere 
using a balloon and then 10-12ml of Dichloromethane (dry freshly distilled) was 
added. The reaction mixture is cooled to -10oC using ice-methanol mixture. DIPEA 
(10 mgs, 0.077 mmol, 3 equiv) was added immediately at this followed by addition of 
Artesunate (10 mgs, 0.026mmol, 1equiv), HATU (10.7 mgs, 0.028 mmol, 1.1equiv) 
and HOAt (38.5 mgs, 0.028 mmol, 1.1equiv) is added in the sequence respectively. 
The reaction is maintained under Ar atmosphere and -10oC till the addition of the 
above components is complete. The reaction is cooled to room temperature gradually 
and stirring is continued at room temperature till TLC shows the product spot. The 
product was isolated by washing the reaction mixture with water and separating the 
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dichloromethane layer. DCM was distilled under vacuum and the residue was purified 
by flash chromatography (2% - 4% MeOH inCHCl3+ 0.1% TEA) in 60% yield. 
 
Artesunate probe (51) – Following the above procedure and purification by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was obtained 
in 99% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.20. IR(KBr)/cm-1 – 3325, 2878, 
2484, 1604, 1404, 1165. 1H(500MHz,CDCl3) δ 7.56(1H, d, Ar-CH, J= 7.4Hz), 
6.74(1H, dd, Ar-CH ,J=2.6Hz, 9.5Hz), 6.52(1H, d, Ar-CH, J=2.5Hz), 6.02(1H, b, -
NH-), 5.63(1H, d, O-CH-OCO, J= 9.45Hz, α- epimer Artesunate), 5.45(1H, s, 
Artesunate-O-CH-O), 5.16(1H, s, Ar-CH-), 3.65(2H, m, Cou-NHCO-CH2-CH2-
NHCO-Artesunate, J=4.4Hz), 3.30(4H, m, Coum-CH2-CONH-, Cou-NHCO-CH2-
CH2-NHCO-Artesunate), 3.04(6H, s, -N(CH3)2), 0.78-2.73(25H, m, Artesunate 
protons),; 13C (500 MHz, MeOD) δ 174.88, 173.53, 171.4, 164.3, 157.3, 154.8, 152.8, 
127.2, 110.8, 110.6, 110.0, 105.6, 98.8, 93.8, 92.8, 81.3, 54.8, 52.8, 46.5, 40.9, 40.2, 
39.5, 38.2, 37.2, 35.2, 32.9, 31.2, 30.4, 25.9, 25.7, 22.8, 20.5, 12.3. MS (ES+): m/z - 
678.2 [M+Na]+.  HRMS (ES+) m/z - calc. 678.2997, obsvd. – 678.2994. LCMS 
Purity -96%. Rt = 8.41-8.55 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O. 
 
Artesunate probe (53) – Following the above procedure and purification by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was obtained 
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in 99% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.40. IR(KBr)/cm-1 – 3496, 3318, 
2924, 2878, 1713, 1659, 1612, 1535, 1404, 1010. 1H (500MHz, CDCl3) δ 7.51(1H, d, 
Chlor-CH, J= 9.1Hz), 6.72(1H, b, COCH2CH2CO-NH-CH-), 6.65(1H, dd, (CH3)2N-
C-CH- , J=2.6Hz, 9.5Hz), 6.48(1H, d, Cou-CH, J= 5.7Hz), 6.38(1H, b, CO-NH-
CH2CH2-), 6.18(1H, s, Cou-OCO-CH-CH-CH2), 5.67(1H, d, -O-CH-OCO, J= 
9.45Hz, α-epimer Artesunate), 5.44(1H, s, O-CH-O Artesunate), 3.61(2H, s, Coum-
CH2-CONH-), 3.3-3.5 (12H, m), 3.31(6H, s, -N(CH3)2), 0.81-2.80(25H, m, Artesunate 
protons); 13C(500 MHz, CDCl3) δ – 171.9, 171.4, 168.2, 161.9, 156.0, 153.1, 150.1, 
125.8, 110.2, 109.1, 108.5, 104.4, 98.2, 92.2, 91.5, 80.1, 70.3, 70.2, 70.2, 70.2, 69.8, 
69.5, 68.7, 53.4, 51.5, 45.2, 40.4, 40.1, 39.6, 39.3, 37.2, 36.2, 34.1, 31.8, 30.7, 29.7, 
25.9, 24.5, 21.9, 20.2, 12.0. MS (ES+): m/z (%): 766.2  [M+Na]+. HRMS (ES+) m/z 
calc. – 766.3521 , observed – 766.3521. LCMS Purity -96%. Rt = 12.2-12.4 min. 
Eluent system – 0% ACN/H2O – 100% ACN/H2O. 
 
Artelinic acid-Coumarin probe (57) – Following the above procedure and purification 
by flash chromatography (2% -6% MeOH in CHCl3+0.1%TEA) the compound was 
obtained in 80% yield. Rf (MeOH:CH2Cl2+0.1%TEA) = 0.75. IR (KBr)/cm-1 – 3400, 
2450, 2400, 1700, 1650, 1625, 1525. 1H (300MHz, MeOD) δ – 7.66(2H, d, Ar-CH, 
J=8.22Hz), 7.34-7.68(1H, d, Ar-H, J=8.88Hz), 7.35(2H, d, Ar-CH, J=8.22Hz), 6.43-
6.56(1H,dd, Ar-H, J=2.6Hz, 6.6Hz), 6.44(1H,d, Ar-H, J=2.6Hz), 6.04(1H,s, Ar-H), 
5.45(1H, s, -O-CH-O), 4.55(1H, 4.58(1H, d, β-CH-O, J=12.7Hz), 3.66(2H, s, -
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NHCO-CH2-), 3.45-3.51(4H, m, -NH-CH2-CH2-NH-), 2.99(6H,s, N(CH3)2), 0.87-2.63 
(20H, m, Artemisinin-CH-); 13C (300 MHz, MeOD) δ 171.8, 170.2,164.23, 157.1, 
154.6, 152.5, 143.4, 134.5, 128.4, 128.3, 126.7, 110.8, 110.6, 109.7, 105.5, 102.7, 
98.7, 89.4, 82.2, 70.3, 53.9, 48.2, 45.8, 40.9, 40.3, 40.2, 38.7, 37.4, 35.8, 32.4, 26.1, 
25.9, 25.8, 20.7, 13.5, 6.02. MS (ES+): m/z (%): 712.1 [M+Na]+. HRMS (ES+) m/z 
calc. – 712.3205, observed – 712.3231. LCMS Purity -96%. Rt = 15.9 - 16.1 min. 
Eluent system – 10% ACN/H2O – 100% ACN/H2O. 
Artelinic-TAMRA probe (83) 
 
Following the above procedure and purification by flash chromatography (10% -20% 
MeOH in CHCl3) the compound was obtained in 70% yield. Rf (MeOH:CH2Cl2) = 
0.25. IR (KBr)/cm-1 – 3446, 2918, 2848, 1647, 1595, 1346, 1188, 1136. 1H (500MHz, 
MeOD) δ 8.07-8.17(2H, d, Ar-H, J=8.2Hz, 8.2Hz), 7.62-7.72(4H, m, Ar-H), 7.32(2H, 
d, Ar-CH, J=8.20Hz), 7.19(2H, d, Ar-CH, J=9.45), 6.90-6.99(3H, m, Ar-H), 5.43(1H, 
s, -O-CH-O), 4.52(1H, d, β-CH-O, J=12.6Hz), 4.22(1H,m, Artemisinin-CH-), 
3.60(4H,m, -NH-CH2-CH2-NH-), 3.30(12H,s, (-NH(CH3)2)2), 1.35-2.69 (23H, m, 
Artemisinin-CH-); 13C (500 MHz, MeOD) δ 170.3, 170.1, 169.3. 169.1, 159.1, 158.8, 
143.4, 136.9, 134.7, 133.6, 132.6, 132.4, 131.4, 129.9, 129.7, 129.6, 128.5, 128.4, 
115.1, 114.9, 105.5, 102.5, 97.4, 89.4, 82.2, 69.0, 54.0, 45.8, 41.1, 40.9, 40.7, 40.2, 
38.7, 37.4, 35.8, 32.3, 31.6, 30.1, 26.1, 25.9, 25.7, 25.0, 24.0, 20.7, 14.4, 13.4, 11.4.  
MS (ES+): m/z (%): 873.3 [M]+. HRMS (ES+) m/z calc. – 873.4069, observed – 
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873.4062. LCMS Purity -96%. Rt = 15.1 - 15.4 min. Eluent system – 0% ACN/H2O – 
100% ACN/H2O. 
Artelinic acid-BODIPY probe (86) 
 
Following the above procedure and purification by flash chromatography (10% -20% 
MeOH in CHCl3) the compound was obtained in 80% yield. Rf (MeOH:CH2Cl2) = 
0.55. IR (pellet)/cm-1 – 3379, 2922, 2853, 1714, 1657, 1606, 1537, 1447, 1252. 1H 
(500MHz, MeOD) δ 7.77(2H, d, Ar-CH, J=8.2Hz), 7.41(2H, d, Ar-CH, J=8.2), 
7.34(1H, s, N-C-CH-C-N+), 6.89(1H, d, Ar-CH-, J=4.4Hz), 6.28(1H, d, Ar-CH-, 
J=4Hz), 6.20(1H, s, Ar-CH-), 5.43(1H, s, Artelinic-CH), 4.82(2H, s, O-CH2-Ph), 
4.54(1H, d, J=12.6Hz, β-isomer, O-CH-O), 3.40-3.50(4H, m, -CONH-CH2-CH2-NH-
), 3.23(2H, t, BODIPY-CH2-, J= 7.6Hz), 2.64(2H, t, BODIPY-CH2-, J= 7.6Hz), 1.19-
2.56(27H, m,s,s, Artelinic acid-CH-, BODIPY-CH3); 13C (500 MHz, MeOD) δ 175.4, 
170.2, 158.4, 145.7, 143.4, 134.7, 132.4, 129.6, 128.5, 128.4, 125.8, 121.4, 117.5, 
105.4, 102.7, 89.3, 82.2, 70.3, 69.1, 65.3, 61.3, 53.9, 45.8, 43.2, 41.2. 40.2, 39.9, 38.6, 
37.4, 35.9, 35.7, 32.3, 31.3, 30.7, 30.3, 30.1, 28.7, 26.1, 25.8, 25.7, 25.6, 24.9, 24.2, 
24.0, 20.7, 14.9, 14.4, 13.4, 11.4, 11.2. MS (ES+): m/z (%): 757.19 [M+Na]+. HRMS 
(ES+) m/z calc. – 757.3561 , observed – 757.3575. LCMS Purity -96%. Rt = 17.2-
17.6 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O. 
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Deoxocarbaartemisinin-Coumarin probe (98) 
 
Following the above procedure and purification by flash chromatography (10% -20% 
MeOH in CHCl3) the compound was obtained in 70% yield. Rf (9:1 MeOH:CH2Cl2) 
= 0.55. IR(KBr)/cm-1 – 3294, 2957, 2926, 2857, 1719, 1618, 1533,1375, 1278, 1128, 
1042. 1H (500MHz, MeOD) δ – 7.71(1H, d, Ar-CH, J=8.88Hz), 6.77(1H,dd, Ar-H, 
J=2.6Hz, 6.6Hz), 6.55(1H,d, Ar-H, J=2.6Hz), 6.05(1H,s, Ar-H), 5.25(1H, s, -O-CH-
O), 3.8 (1H, m, β-CH-O, J=12.7Hz), 3.69(2H, s, -NHCO-CH2-), 3.25-3.50(4H, m, -
NH-CH2-CH2-NH-), 3.09(6H,s, N(CH3)2), 0.77-2.60 (23H, m, Artemisinin-CH-); 13C 
(300 MHz, MeOD) δ 174.0, 171.3, 164.2, 157.2, 154.8, 152.8, 126.9, 126.8, 110.6, 
110.2, 105.6, 98.8, 93.2, 82.3, 73.2, 53.1, 47.2, 41.0, 40.5, 40.3, 40.2, 39.9, 38.4, 37.2, 
35.2, 32.6, 26.2, 25.9, 22.2, 20.6, 14.1. MS (ES+):  m/z (%): 620.2 [M+Na]+. HRMS 
(ES+) m/z calc. – 598.3123  , observed – 598.3119 [M+H]+ . LCMS Purity -96%. Rt 
= 14.95 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O +0.01%TFA. 
Deoxocarbaartemisinin-BODIPY probe (100) 
 
Following the above procedure and purification by flash chromatography (10% -20% 
MeOH in CHCl3) the compound was obtained in 70% yield. Rf (9:1 MeOH:CH2Cl2) 
= 0.55. IR (KBr)/cm-1 – 3350, 2954, 2926, 1724, 1647, 1607, 1529, 1437, 1252, 1134. 
1H (500MHz, MeOD) δ 7.45(1H, s, N-C-CH-C-N+), 7.01(1H, d, Ar-CH-, J=3.8Hz), 
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6.31(1H, d, Ar-CH-, J=3.8Hz), 6.21(1H, s, Ar-CH-), 5.24(1H, s, Artelinic-CH), 
3.85(1H, sex, J=12.6Hz, β-isomer, O-CH-O), 3.15-3.55(6H, m, -CONH-CH2-CH2-
NH-, BODIPY-CH2-), 0.79-2.70(33H, m,s,s, Artemisinin-CH-, BODIPY-CH3, 
BODIPY-CH2-); 13C (500 MHz, MeOD) δ 174.9, 174.0, 161.2, 158.9, 145.7, 136.5, 
134.9, 129.8, 125.8, 121.4, 117.8, 105.6, 104.6, 93.2, 90.8, 82.3, 82.1, 73.7, 73.3, 
53.6, 53.2, 47.2, 45.4, 41.3. 40.2, 39.9, 39.8, 39.4, 38.7, 38.3, 38.2, 37.4, 37.2, 36.4, 
36.2, 35.6, 35.2, 32.9, 31.5, 26.1, 25.9, 25.7, 25.68, 24.65, 22.2, 20.6, 20.5, 14.9, 14.0, 
13.0, 11.2. MS (ES+): m/z (%): 665.2 [M+Na]+. HRMS (ES+) m/z calc. – 643.3479, 
observed – 643.3508 [M+H]+. LCMS Purity -96%. Rt =  16.33 min. Eluent system – 
0% ACN/H2O – 100% ACN/H2O +0.01%TFA.. 
 
5.1.20 Synthesis of Artelinic Acid – 
 
β-Artelinic Acid (49) – Following the procedure for synthesis of artelinic acid as 
shown in literature and purification by flash chromatography (50% EtOAc in Hexane) 
the compound was obtained in 65% yield. Rf (50% EtOAc in Hexane) = 0.5. IR 
(KBr)/cm-1 – 3500, 3000, 1750, 1390, 1350. 1H (300MHz, MeOD) δ 8.00(2H, d, Ar-
CH, J=8.37Hz), 7.43(2H, d, Ar-CH, J=8.37), 5.44(1H, s, -O-CH-O), 4.58(1H, d, β-
CH-O, J=12.8Hz), 0.9-2.62 (22H, m, Artemisinin-CH-, -CH3-),  13C (300 MHz, 
MeOD) δ 145.0, 130.9, 128.3, 105.5, 102.8, 89.4, 82.2, 70.3, 57.4, 53.9, 45.8, 38.7, 
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37.4, 32.4, 26.1, 25.8, 25.7, 20.7, 13.4. MS (ES+): m/z (%):  440.94 [M+Na]+. LCMS 
Purity -98%. Rt = 16.4 - 16.6 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O. 
 
5.1.21 Synthesis of β–Deoxocarbaartemisinin (97)64 – 
 
Dihydroartemisinin 10α- benzoate (95) – Following the procedure for synthesis of 
Dihydroartemisinin 10α- benzoate as shown in literature64 and purification by flash 
chromatography (10% EtOAc in Hexane) the compound was obtained in 92% yield. 
Rf (10% EtOAc in Hexane) = 0.3. 1H (500MHz, CDCl3) δ 8.13 (2H, d, Ar-CH-, J= 
7.6 Hz), 7.57 (1H, m, Ar-CH-, J= 7.6 Hz), 7.45 (2H, m, aromatic, J= 8.2 Hz), 6.05 
(1H, d, J= 10Hz, α-epimer), 5.53 (1H, s), 2.76 (1H, m), 2.40 (1H, m), 0.93-2.07 (19 
H, m); 13C (500MHz, CDCl3) δ 165.9, 133.9, 130.8, 130.3, 128.9, 105.1, 93.2, 92.3, 
80.9, 52.3, 46.0, 37.9, 36.9, 34.8, 32.7, 26.6, 25.3, 22.7, 20.9, 13.9. MS (ES+): m/z 
(%): 410.96 [M+Na]+  . 
 
10-β-Allyldeoxoartemisinin (96) – Following the procedure for synthesis of 10-β-
Allyldeoxoartemisinin as shown in literature64 and purification by flash 
chromatography (10% EtOAc in Hexane) the compound was obtained in 70% yield. 
Rf (10% EtOAc in Hexane) = 0.5. 1H (500MHz, CDCl3) δ 5.91 (1H, m), 5.30 (1H, s, -
O-CH-O), 5.08(2H,m), 4.29(1H,m, J= 12.6Hz, β-CH-O, β-epimer), 2.68 (1H, sex, 
J=6.3Hz), 0.89-2.43 (21H, m, Artemisinin-CH), δc (500MHz, CDCl3) - 137.2, 116.8, 
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103.8, 89.8, 81.8, 75.4, 53.0, 45.0, 38.2, 37.3, 35.2, 34.9, 30.9, 26.8, 25.6, 25.4, 20.9, 
13.7. MS (ES+): m/z (%): 331.02 [M+Na]+ . 
 
10-β-Deoxocarbaartemisinin carboxylic acid (97) – Following the procedure for 
synthesis of 10-β-Allyldeoxoartemisinin as shown in literature64 and purification by 
flash chromatography (10% EtOAc in Hexane) the compound was obtained in 90% 
yield. Rf (10% MeOH/CH2Cl2) = 0.5. 1H (500MHz, CDCl3) δ  5.37 (1H, s, -O-CH-O), 
4.87(1H,m, J= 12.6Hz, β-CH-O, β-epimer), 0.89-2.72 (21H, m, Artemisinin-CH-, -
CH3-); 13C (500MHz, CDCl3) δ 176.2, 103.9, 90.2, 81.5, 71.1, 52.7, 44.4, 38.2, 37.1, 
36.5, 34.9, 30.5, 29.9, 26.5, 25.4, 25.3, 20.7, 13.3. MS (ES+): m/z (%): 349.2 
[M+Na]+. LCMS Purity -96%. Rt = 15.5min. Eluent system – 0% ACN/H2O – 100% 
ACN/H2O. 
5.1.22 General experimental procedure for synthesis of click probes (58-64) 
Alkyne linkage using 3-bromo-prop-1-yne  –  
N-(7-Chloro-4-quinolyl)-N′-ethyl-1,2-diaminoethane (27a) (100mgs, 0.05mmol, 
1equiv.) and freshly dried K2CO3 (125mgs, 0.09mmol, 2equiv.) were stirred together 
in a single neck flask under Ar atmosphere in 2-3ml of dry Acetonitrile. 3-bromo-
prop-1-yne (54mgs, 0.05mmol, 1equiv.) was added directly to the above reaction 
mixture at 4oC (Ice water). Ice Water is removed after the addition is done and the 
reaction is stirred at room temperature for 12hrs. After confirmation of formation of 
product by TLC (9:1 CH2Cl2:MeOH+0.1%TEA). The reaction mixture is columned 
through Celite and 50ml of Acetonitrile is added to extract the product from the 
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column. Acetonitrile is distilled under vacuum and the residue is purified by flash 
chromatography (2% -6% MeOH in CHCl3+0.1%TEA).  
 
N1-(7-chloroquinolin-4-yl)-N2-(prop-2-ynyl)ethane-1,2-diamine (63a) –  
Following the above procedure and purification by flash chromatography (4% -8% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 30% yield. Rf 
(MeOH:CH2Cl2+0.1%TEA) = 0.35. IR (KBr)/cm-1 – 3200, 3100, 1575. 1H (300MHz, 
MeOD) δ –   8.29(1H, d, -N=CH-, J=5.7Hz), 8.03(1H, d, Ar-CH, J=8.8Hz), 7.77(1H, 
d, Ar-H, J=2.6Hz), 7.33(1H, dd, Ar-H, J=2.5Hz,J=6.93Hz), 6.52(1H, d, Ar-H, J = 
5.7Hz), 3.39-3.46(2H, t, NH-CH2-CH2-NH, J=6.4Hz; 2H, m, -CH2-Alkyne, J=2.6Hz), 
2.96(2H, t, NH-CH2-CH2-NH,, J=6.4Hz), 2.56(1H, m, Alkyne-CH-, J=2.6Hz); 13C 
(500 MHz, MeOD) δ 152.9, 152.2, 149.4, 136.5, 127.4, 126.2,  124.4, 99.7, 81.9, 
73.5, 47.3, 43.2, 42.1, 38.3. MS (ES+): m/z (%):  260.1 [M+H]+. HRMS m/z calc. – 
260.0949 , observed – 260.0955. LCMS Purity -96%. Rt = 10.0 - 10.3 min. Eluent 
system – 0% ACN/H2O – 100% ACN/H2O. 
 
N1-(7-chloroquinolin-4-yl)-N4-(prop-2-ynyl)butane-1,4-diamine (63b) – Following 
the above procedure and purification by flash chromatography (4% -8% MeOH in 
CHCl3+0.1%TEA) the compound was obtained in 25% yield. Rf 
(MeOH:CH2Cl2+0.1%TEA) = 0.35. IR (KBr)/cm-1 – 3200, 3100, 1575.  1H(300MHz, 
MeOD) δ 8.22(1H, d, -N=CH-, J=5.7Hz), 7.98(1H, d, Ar-CH, J=8.8Hz), 7.65(1H, d, 
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Ar-H, J=2.6Hz), 7.27(1H, dd, Ar-H, J=2.5Hz, J=6.9Hz), 6.39(1H, d, Ar-H, J = 
5.7Hz), 3.21-3.30(2H,m,-CH2-Alkyne, J=2.6Hz; 2H, t, -NH-CH2-(CH2)2-CH2-NH-, 
J=6.4Hz ), 2.51-2.65 (2H, t, -NH-CH2-(CH2)2-CH2-NH-, J=6.4Hz; 1H, s, Alkyne-CH-
), 1.49-1.71(4H, m, -NH-CH2-(CH2)2-CH2-NH-); 13C (500 MHz, MeOD) δ 152.9, 
152.1, 149.3, 136.4, 127.3, 126.9, 124.4, 118.7, 99.6, 81.9, 73.3, 43.8, 38.4, 27.8, 
27.1. MS (ES+): m/z (%):  288.1 [M+H]+. HRMS m/z calc. – 288.1262 , observed – 
288.1267. LCMS Purity -96%. Rt = 4.0 - 4.1 min. Eluent system – 0% ACN/H2O – 
100% ACN/H2O. 
 
N1-(7-chloroquinolin-4-yl)-N2,N2-di(prop-2-ynyl)ethane-1,2-diamine (64a) – 
Following the above procedure and purification by flash chromatography (2% -4% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 70% yield. Rf 
(MeOH:CH2Cl2+0.1%TEA) = 0.7. IR(KBr)/cm-1 – 3200, 1625, 1600, 1575. 1H 
(300MHz, MeOD) δ 8.27(1H, d, -N=CH-, J=5.7Hz), 7.93(1H, d, Ar-CH, J=8.8Hz), 
7.30(1H, dd, Ar-H, J=2.5Hz), 7.68(1H, d, Ar-H, J=2.6Hz), 6.46(1H, d, Ar-H, J = 
5.7Hz),  2.60(2H, t, Alkyne-CH-), 3.46 (4H, m, -CH2-Alkyne, J=2.3Hz), 3.40 (4H, t,-
NH-CH2-CH2-NH-, J=6.8Hz), 2.85(2H, t, -NH-CH2-CH2-NH-, J=6.8Hz), 2.60(2H, m, 
Alkyne-CH-, J=2.3Hz); 13C(500 MHz, MeOD) δ 152.5, 149.6, 136.4, 127.6, 126.1, 
124.1, 118.7, 99.8, 79.2, 75.0, 51.7, 43.1, 41.42. MS (ES+): m/z (%):  298.1 [M+H]+. 
HRMS m/z calc. – 298.1106 , observed – 298.1110. LCMS Purity -96%. Rt = 14.9 - 
15.2 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O. 




N1-(7-chloroquinolin-4-yl)-N4,N4-di(prop-2-ynyl)butane-1,4-diamine (64b) – 
Following the above procedure and purification by flash chromatography (2% -4% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 70% yield. Rf (9:1 
MeOH:CH2Cl2+0.1%TEA) = 0.7. IR (pellet)/cm-1 – 3200, 1625, 1600, 1575. 1H 
(300MHz, MeOD) δ 8.24(1H, d, -N=CH-, J=5.7Hz), 7.97(1H, d, Ar-CH, J=8.8Hz), 
7.66(1H, d, Ar-H, J=2.6Hz), 7.28(1H, dd, Ar-H, J=2.5Hz, J=6.8Hz), 6.42(1H, d, Ar-
H, J = 5.7Hz), 3.46 (4H, m, -CH2-Alkyne, J=2.3Hz), 3.22 (4H, t,-NH-CH2-(CH2)2-
CH2-NH-, J=6.8Hz), 2.47-2.55 (2H, t, -NH-CH2-(CH2)2-CH2-NH-, J=6.8Hz; 2H, m, 
Alkyne-CH-, J=2.3Hz), 1.38-1.72 (4H, t, -NH-CH2-(CH2)2-CH2-NH-, J=6.8Hz); 13C 
(500 MHz, MeOD) δ 152.7, 152.3, 149.6, 136.3, 127.5, 125.9, 124.3, 118.7, 99.7, 
79.1, 74.9, 74.8, 53.4, 43.7, 42.7, 27.0, 25.6. MS (ES+): m/z (%):  326.1 [M+H]+. 
HRMS m/z calc. – 326.1419, observed – 326.1424. LCMS Purity -96%. Rt = 9.2 – 
9.3 min. Eluent system – 0% ACN/H2O – 100% ACN/H2O. 
 
N1-(7-chloroquinolin-4-yl)-N2-ethyl-N2-(prop-2-ynyl)ethane-1,2-diamine (58) – 
Following the above procedure and purification by flash chromatography (2% -4% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 60% yield. Rf (9:1 
MeOH:CH2Cl2+0.1%TEA) = 0.65. IR (KBr)/cm-1 – 3200, 3100, 1575. 1H (300MHz, 
MeOD) δ  8.27(1H, d, -N=CH-, J=5.7Hz), 7.93(1H, d, Ar-CH, J=8.8Hz), 7.68(1H, d, 
Ar-H, J=2.6Hz), 7.30(1H, dd, Ar-H, J=2.5Hz, J=6.9Hz), 6.46(1H, d, Ar-H, J = 
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5.7Hz), 3.36-3.45(2H, m, -CH2-Alkyne, J=2.5Hz; 2H, t, NH-CH2-CH2-NH, J=6.8Hz), 
2.55-2.82(2H, t, NH-CH2-CH2-NH, J=6.8Hz; 4H, m, Alkyne-CH-, N-CH2-CH3-), 
1.01(3H, t, -CH2-CH3-, J=7.1Hz),; 13C (300 MHz, MeOD) δ  152.5, 152.4,  149.6, 
136.4, 127.6, 126.1, 124.1, 118.7, 99.8, 78.7, 75.1, 52.2, 42.0, 41.5, 12.7. MS (ES+): 
m/z (%):  288.1 [M+H]+. HRMS m/z calc. – 288.1262, observed – 288.1263. LCMS 
Purity - 96%. Rt = 8.1 – 8.2 min. Eluent system – 0% ACN/H2O+0.1%TFA – 100% 
ACN/H2O+0.1%TFA. 
Alkyne linkage using prop-2-yn-1-amine (59, 61,86,87) – 
Coumarin-4-acetic acid (34) (50mgs, 0.2mmol, 1equiv.) was added under Ar 
atmosphere and 5 ml of anhydrous CH2Cl2 was added to above reactant. The reaction 
mixture was cooled to 4oC using Ice bath and then HATU (8.5 mgs, 0.22 mmol, 1.1 
equiv) and HOAt (3 mgs, 0.22 mmol, 1.1equiv), prop-2-yn-1-amine (11mgs, 
0.2mmol, 1equiv) was added in the sequence respectively. The reaction is maintained 
under Ar atmosphere and 4oC till the addition of the above components is complete. 
The reaction is cooled to room temperature gradually and stirring is continued at room 
temperature till TLC shows the product spot. The product was isolated by washing the 
reaction mixture with water and brine and collecting the organic fraction. The organic 
fraction was evaporated and the residue was purified by flash chromatography (2% - 
4% MeOH inCHCl3+ 0.1% TEA) (41mgs) 40% yield. 
In case of TAMRA (81) based intermediates the procedure enclosed below is 
followed. 6-TAMRA-COOH (81) (100 mgs, 0.22 mmol, 1.0equiv) is added to flame 
dried single necked flask containing dry THF 5mL. The reaction mixture was cooled 
to -10oC and then ethylchloroformate (33mgs, 0.35 mmol, 1.5equiv) and TEA(       
40mgs, 0.35 mmol, 1.5equiv). The reaction mixture is stirred for 1hr at this 
temperature and then prop-2-yn-1-amine (19 mgs, 0.44 mmol, 2 equiv) is added in 
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liquid form directly to the reaction mixture at -10oC. The reaction mixture is gradually 
cooled to room temperature and stirred for 16-18hrs. After confirmation with TLC, 
the solvent is removed under vacuum and then the crude is purified by column 
chromatography (10% -15% MeOH in CHCl3). 
 
 
2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)-N-(prop-2-ynyl)acetamide (59) – 
Following the above procedure and purification by flash chromatography (4% -8% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 40% yield. Rf (9:1 
MeOH:CH2Cl2+0.1%TEA) = 0.45. IR (KBr)/cm-1 – 3400, 3300, 2900, 2850, 1700, 
1650, 1625, 1525. 1H (300MHz, DMSO-d6) δ 8.64(1H, bs, -NH-), 7.52(1H, d, Ar-
CH-, J= 9.1Hz), 6.72(2H, dd, Ar-CH-, J=2.6Hz, J=6.4Hz), 6.55(2H, d, Ar-CH- 
J=2.6Hz), 5.76(1H, s, Ar-CH-), 3.87(2H, m, -CH2-Alkyne,J=2.5Hz), 3.63(2H, s, -
NHCO-CH2-),3.14(1H, m, Alkyne-CH-, J=2.5Hz), 3.01(6H,s, N(CH3)2); 13C(300 
MHz, DMSO-d6) δ 177.1, 167.7, 160.6, 155.4, 152.8, 150.9, 125.9, 109.3, 109.0, 
108.1, 97.5, 96.4, 85.4, 80.8, 73.3, 71.9, 28.2. MS (ES+): m/z (%): 285.1 [M+H]+. 
HRMS (ES+) m/z calc. – 285.1240, observed – 285.1234. LCMS Purity - 96%. Rt = 
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Artelinate Alkyne (61) – Following the above procedure and purification by flash 
chromatography (50% EtOAc in Hexane) the compound was obtained in 65% yield. 
Rf (50% EtOAc in Hexane) = 0.5. IR (KBr)/cm-1 – 3400, 2950, 1650. 1H (300MHz, 
MeOD) δ 7.75(2H, d, Ar-CH, J=8.4Hz), 7.38(2H, d, Ar-CH, J=8.4Hz), 5.38(1H, s, -
O-CH-O), 4.51(1H, d, β-CH-O, J=12.8Hz), 4.08 (2H, m, Alkyne-CH2-, J=2.5Hz), 0.8-
2.55 (25H, m, Artemisinin-CH-, Alkyne-CH2-); 13C (300 MHz, MeOD) δ 143.8, 
134.4, 128.3, 105.5, 102.7, 101.7, 89.4, 82.2, 80.8, 72.0, 70.3, 53.9, 45.8, 38.7, 37.4, 
35.8, 32.4, 26.1, 25.8, 25.7, 20.7, 13.4. MS (ES+): m/z (%): 478 [M+Na]+. HRMS 
(ES+) m/z calc. – 478.2200 , observed – 478.2203 . LCMS Purity - 96%. Rt = 15.7-
15.9 min. Eluent system – 5% ACN/H2O – 100% ACN/H2O. 
 
TAMRA Alkyne (87) – 
Following the procedure for TAMRA activation and coupling as described above and 
purification by flash chromatography (10% MeOH:CH2Cl2+0.1%TEA) the compound 
was obtained in 65% yield. Rf(10% MeOH:CH2Cl2+0.1%TEA)= 0.25. IR (KBr)/cm-1 
– 3417, 1621, 1600, 1406, 1366, 1186, 1134. 1H (500MHz, DMSO-d6) δ 9.18(1H,b, -
NH-), 8.08-8.19 (2H, d,d, Ar-CH, J=8.2Hz, J=8.2Hz), 7.68(1H, s, Ar-CH), 6.55(6H, 
bs, Ar-CH), 3.99(2H,m, Alkyne-CH2, J=2.6Hz), 3.08(1H, s, Alkyne-CH, J=2.6Hz), 
2.97(12H, s, (-NH-(CH3)2)2); 13C(500MHz, DMSO-d6) δ 164.3, 129.2, 128.7, 97.8, 
80.7, 73.0, 28.6, 8.4. MS (ES+): m/z (%): 468.3 [M+H]+. HRMS (ES+) m/z calc. – 
468.1918 , observed – 468.1931. LCMS Purity - 96%. Rt = 9.4-9.7 min. Eluent 
system – 0% ACN/H2O – 100% ACN/H2O. 
 




BODIPY Alkyne (88) – 
Following the above procedure and purification by flash chromatography (6% -8% 
MeOH in CHCl3) the compound was obtained in 80% yield. Rf (50% EtAc:Hex) = 
0.75. IR(KBr)/cm-1 – 3319, 3280, 2922, 2852, 1654, 1533, 1485.  1H (500MHz, 
MeOD) δ 7.42(1H, s, N-C-CH-C-N+), 6.99(1H, d, Ar-CH-, J=4.0Hz), 6.32(1H, d, Ar-
CH-,J=4.4Hz), 6.20(1H, s, Ar-CH-), 3.96(2H, m, Alkyne-CH2, J=2.6Hz), 3.22(2H, t, 
BODIPY-CH2, J=6.9), 2.57-2.63(2H, t, BODIPY-CH2, J=6.9Hz; 1H, m, Alkyne-CH, 
J=2.6Hz), 2.51 (3H, s, BODIPY-CH3), 2.27 (3H, s, BODIPY-CH3); 13C(500 MHz, 
MeOD) δ 174.2, 161.3, 158.4, 129.6, 125.8, 121.3, 117.7, 80.6, 72.2, 54.8, 35.7, 29.5, 
25.4, 14.8, 11.2. MS (ES+) m/z (%): 352.09[M+Na]+. HRMS (ES+) m/z calc. – 
352.1406 , obsvd. – 352.1420. LCMS Purity - 96%. Rt = 13.9-14.2 min. Eluent 
system – 5% ACN/H2O – 100% ACN/H2O. 
 
β-Deoxocarbaartemisinin alkyne (104) – Following the above procedure and 
purification by flash chromatography (6% -8% MeOH in CHCl3) the compound was 
obtained in 77% yield. Rf (50% EtAc:Hex) = 0.65. IR(KBr)/cm-1 – 3361, 2955, 2859, 
1676, 1526, 1458, 1383. 1H (500MHz, CDCl3) δ  5.39 (1H, s, -O-CH-O), 4.87(1H,m, 
J= 12.6Hz, β-CH-O), 4.05(2H, m, Alkyne-CH2, J=2.9Hz), 0.89-2.72 (20H, m, 
Artesunate-CH-, -CH3-; 1H, m, Alkyne-CH, J=2.9Hz); 13C (500MHz, CDCl3) δ 
172.1, 103.6, 90.9, 81.5,80.5, 71.9, 69.7, 52.4, 43.9, 38.2, 38.1, 37.2, 34.9, 31.1, 29.6, 
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29.5, 25.5, 20.7, 12.6. MS (ES+) m/z (%): 388.06 [M+Na]+. HRMS (ES+) m/z calc. – 
364.2118, obsvd. – 364.2125 [M+H]+. LCMS Purity - 96%. Rt = 14.7-14.9 min. 
Eluent system – 0% ACN/H2O – 100% ACN/H2O+0.1% TFA. 
Azide linkage (60, 62) – 
Coumarin acetic acid (34) (100mgs, 0.4mmol, 1equiv.) was added under Ar 
atmosphere and 2.5ml of anhydrous CH2Cl2 was added to above reactant. The 
reaction mixture was cooled to -10oC using Ice bath and then DIPEA (209 mgs, 
1.62mmol, 4 equiv), HATU (169mgs, 0.44 mmol, 1.1equiv), HOAt (61mgs, 0.44 
mmol, 1.1 equiv) and 3-Azido propanamine (35mgs, 0.4mmol, 1equiv) was added in 
the sequence respectively. The reaction is maintained under Ar atmosphere and -10oC 
till the addition of the above components is complete. The reaction is cooled to room 
temperature gradually and stirring is continued at room temperature till TLC shows 
the product spot. The product was isolated by removing the reaction mixture under 
vacuum and the residue was purified by flash chromatography (4% - 8% MeOH 
inCHCl3+ 0.1% TEA) 70% yield. 
In case of TAMRA (81) based intermediates the procedure enclosed below is 
followed. 6-TAMRA-COOH (81) (53mgs, 0.16 mmol,1.0equiv) is added to flame 
dried single necked flask containing dry THF 5mL. The reaction mixture was cooled 
to -10oC and then ethyl chloroformate (20mgs (33µL), 0.19 mmol, 1.5equiv) and TEA 
(35mgs (48µL), 0.19 mmol, 1.5equiv). The reaction mixture is stirred for 1hr at this 
temperature and then 2-Azidoethylamine (22mgs, 0.25mmol, 1.5equiv) is added in 
liquid form directly to the reaction mixture at -10oC. The reaction mixture is gradually 
cooled to room temperature and stirred for 16-18hrs. After confirmation with TLC, 
the solvent is removed under vacuum and then the crude is purified by column 
chromatography (10% -15% MeOH in CHCl3). 




N-(2-azidoethyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamide (60) – 
Following the above procedure and purification by flash chromatography (4% -8% 
MeOH in CHCl3+0.1%TEA) the compound was obtained in 70% yield. Rf (10% 
MeOH:CH2Cl2) = 0.5. IR (KBr)/cm-1 – 3400, 3300, 2950, 1700, 1650, 1600, 1550. 1H 
(300MHz, MeOD) δ 7.47(1H, d, Ar-CH-, J=9Hz), 6.66 (1H, dd, Ar-CH-, J=2.5Hz, 
6.6Hz), 6.46 (1H, d, Ar-CH-, J=2.6Hz), 5.97(1H, s, Ar-CH-), 3.62(2H, s, -NHCO-
CH2-), 3.20-3.3(4H, m, NH-CH2-CH2-N3), 2.98 (6H,s, N(CH3)2); 13C (300 MHz, 
MeOD) δ 171.4, 164.3, 157.2, 154.8, 152.6, 130.1, 126.9, 110.6, 110.5, 109.8, 98.8, 
51.5, 40.2, 40.2, 40.1. MS (ES+): m/z (%): 316.1[M+H]+  338.0[M+Na]+. HRMS 
(ES+) m/z calc. – 338.1218 , observed – 338.1224. LCMS Purity - 96%. Rt = 11.9-
12.1 min. Eluent system – 5% ACN/H2O – 100% ACN/H2O. 
 
Artelinate Azide (62) – Following the above procedure and purification by flash 
chromatography (50% EtOAc in Hexane) the compound was obtained in 65% yield. 
Rf (50% EtOAc in Hexane) = 0.5. IR (KBr)/cm-1 – 3400, 2900, 2100, 1650, 1550. 1H 
(300MHz, MeOD) δ 7.74(2H, d, Ar-CH, J=6.6Hz), 7.38(2H, d, Ar-CH, J=8.8), 
5.38(1H, s, -O-CH-O), 4.58(1H, d, β-CH-O, J=12.8Hz), 3.41-3.53(4H, -NH-CH2-
CH2-N3-), 0.79-2.58 (22H, m, Artemisinin-CH- ); 13C (300 MHz, MeOD) δ 143.7, 
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128.6, 128.5, 105.5, 102.7, 89.4, 82.2, 70.3, 53.9, 51.4, 45.8, 40.6, 38.7, 37.4, 35.8, 
32.4, 26.1, 25.8, 25.7, 20.7, 13.4. MS (ES+): m/z (%): 509.1 [M+Na]+. HRMS (ES+) 
m/z calc. – 509.2368, observed – 509.2371. LCMS Purity - 96%. Rt = 15.9-16.2 min. 
Eluent system – 5% ACN/H2O – 100% ACN/H2O. 
 
TAMRA azide (89) – Following the protocol for TAMRA based probes the above 
compound was obtained in 90% yields. Rf (10% MeOH/DCM) = 0.15. IR (KBr)/cm-1 
– 3415, 2957, 2852, 2106, 1597, 1492, 1365. 1H (500MHz, MeOD) δ 8.19-8.13 (2H, 
d, d, Ar-CH, J=8.2Hz, J=8.2Hz), 7.74(1H, d, Ar-CH, J= 2.0Hz), 7.27(2H, d, Ar-CH, 
J= 9.45Hz), 7.05(2H, dd, Ar-CH, J= 2.5Hz, J= 6.95Hz), 6.96(1H, d, Ar-H, J=2Hz), 
3.30-3.34(4H, m, NH-CH2-CH2-N3), 3.1(12H, s, (-NH-(CH3)2)2) ; 13C(500 MHz, 
MeOD) δ 159.1, 158.8, 132.6, 129.6, 115.2, 97.3, 49.5, 40.9, 39.9. MS (ES+): m/z 
(%): 499.01 [M+H]+. HRMS (ES+) m/z calc. – 499.2088, observed – 499.2093. 
LCMS Purity - 96%. Rt = 12.89-12.93 min. Eluent system – 5% ACN/H2O – 100% 
ACN/H2O. 
 
BODIPY azide (90) – Following the protocol for regular probes the above compound 
was obtained in 85% yields. Rf (10% MeOH/DCM) = 0.5. IR (KBr)/cm-1 – 3292, 
2953, 2926, 2101, 1527, 1442. 1H (500MHz, MeOD) δ 7.37(1H, s, N-C-CH-C-N+), 
6.97(1H, d, Ar-CH-, J=3.8Hz), 6.31(1H, d, Ar-CH-,J=4.4Hz), 6.17(1H, s, Ar-CH-), 
3.36(4H, m, NH-CH2-CH2-N3), 3.22(2H, t, BODIPY-CH2, J=7.6Hz), 2.61(2H, t, 
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BODIPY-CH2, J=8.2Hz), 2.57-2.63(2H, t, BODIPY-CH2, J=6.9Hz; 1H, m, Alkyne-
CH, J=2.6Hz), 2.60 (3H, s, BODIPY-CH3), 2.24 (3H, s, BODIPY-CH3); 13C(500 
MHz, MeOD) δ 174.9, 161.3, 158.4, 145.8, 136.5, 134.9, 129.6, 125.7, 121.3, 117.6, 
51.5, 39.9, 35.9, 25.5, 14.9, 11.2. MS (ES+): m/z (%): 383.05 [M+H]+. HRMS (ES+) 
m/z calc. – 383.1577, observed – 383.1593. LCMS Purity - 96%. Rt = 14.0-14.4 min. 
Eluent system – 0% ACN/H2O – 100% ACN/H2O+0.1%TFA. 
 
β-Deoxocarbaartemisinin azide (105) – Following the above procedure and 
purification by flash chromatography (6% -8% MeOH in CHCl3) the compound was 
obtained in 77% yield. Rf (100% EtAc) = 0.68. IR(KBr)/cm-1 – 3361, 2955, 2859, 
2092, 1674, 1522, 1381. 1H (500MHz, CDCl3) δ  5.39 (1H, s, -O-CH-O), 4.78(1H,m, 
J= 12.6Hz, β-CH-O), 3.58-3.28(1H, m, O-CH-CH2-CO; 2H, m, NH-CH2-CH2-N3; 1H, 
m, O-CH-CH2-CO), 0.86-2.56 (22H, m, Artesunate-CH-, -CH3-); 13C (500MHz, 
CDCl3) δ 172.8, 103.6, 90.9, 81.5, 70.2, 52.4, 51.4, 44.0, 39.5, 38.2, 38.1, 37.2, 34.9, 
31.1, 26.4, 25.5, 20.7, 12.7. MS (ES+) m/z (%): 417.06 [M+Na]+. HRMS (ES+) m/z 
calc. – 395.2289, obsvd. – 395.2292 [M+H]+. LCMS Purity - 96%. Rt = 15.7-15.9 
min. Eluent system – 5% ACN/H2O – 100% ACN/H2O. 
5.1.23 – Synthesis of BODIPY-COOH66 –  
Following the procedure in literature66 the characterization data for the intermediates 
and the final products is listed below. 
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(E)-methyl 3-(1H-pyrrol-2-yl)acrylate (101) – 
Following the procedure as discussed in literature66, and purification by flash 
chromatography (10% EtOAc in Hexane) the compound was obtained in 90% yield. 
Rf (10% EtOAc in Hexane) = 0.15. 1H (300MHz, CDCl3) δ – 9.51(1H, b, -NH-), 
7.62(1H, d, NH-C-CH-CH-CO-, J=26.6Hz, E-enantiomer), 6.93(1H, d, Ar-CH, 
J=1.9Hz), 6.57(1H, s, Ar-CH), 6.29(1H, m, Ar-CH), 6.13(1H, d, NH-C-CH-CH-CO-, 
J=15.9Hz), 3.79 (3H, s, -CO2-CH3-), 6.12(1H, d, NH-C-CH-CH-CO-, J=26.6Hz, E-
enantiomer); 13C (300 MHz, CDCl3) δ – 168.7, 134.9, 128.3, 122.7, 114.5, 110.7, 
110.3, 51.5. MS (ES-): m/z (%): 150.1 [M-H]-. 
           
Methyl 3-(1H-pyrrol-2-yl)propanoate (102) - Following the procedure as discussed in 
literature66, and purification by flash chromatography (10% EtOAc in Hexane) the 
compound was obtained in 95% yield. Rf (10% EtOAc in Hexane) = 0.35. 1H 
(300MHz, CDCl3) δ – 6.69(1H, m, Ar-CH-), 6.15(1H, m, Ar-CH-), 5.97(1H, m, Ar-
CH-), 3.74 (3H, s, -CO2-CH3-), 2.95(2H, t, NH-C-CH-CH-CO-, J=6.9Hz), 2.68(2H, t, 
NH-C-CH2-CH-CO-, J=6.9Hz); 13C (300 MHz, CDCl3) δ – 174.3, 130.7, 116.7, 
107.9, 105.3, 51.6, 34.1, 22.4. MS(ES-): m/z (%): 151.9 [M-H]-. HRMS(ES+) m/z 
calc. – 176.0682, observed – 176.0682[M+Na]+. 
 
5,5-difluoro-3-(3-methoxy-3-oxopropyl)-7,9-dimethyl-5H-dipyrrolo[1,2-c:1',2'-
f][1,3,2]diazaborinin-4-ium-5-uide (103) - Following the procedure as discussed in 
literature66, and purification by flash chromatography (25% EtOAc in Hexane) the 
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compound was obtained in 95% yield. Rf (25% EtOAc in Hexane) = 0.45. 1H 
(500MHz, CDCl3) δ – 7.06(1H, s, N-C-CH-C-N+), 6.85(1H, d, Ar-CH-, J=3.8Hz), 
6.24(1H, d, Ar-CH-, J=3.8Hz), 6.09(1H, s, Ar-CH-), 3.68 (3H, s, -CO2-CH3), 
3.28(2H, t, NH-C-CH-CH-CO-, J=6.9 Hz), 2.76(2H, t, NH-C-CH2-CH-CO-, J=6.9 
Hz), 2.54 (3H, s, -CH3- ), 2.21 (3H, s, -CH3- ),  ; 13C (500 MHz, CDCl3) δ – 172.9, 
160.3, 156.9, 143.8, 135.1, 133.2, 128.0, 123.8, 120.4, 116.5, 51.6, 33.2, 29.6, 23.9, 
14.9, 11.2. MS (ES-): m/z (%): 329.05[M+Na]-. HRMS (ES+) m/z calc. – 329.1246, 
observed – 329.1249. 
 
3-(2-carboxyethyl)-5,5-difluoro-7,9-dimethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diaza 
borinin-4-ium-5-uide (84) - Following the procedure as discussed in literature66, and 
purification by flash chromatography (25% EtOAc in Hexane) the compound was 
obtained in 95% yield. Rf (25% EtOAc in Hexane) = 0.40. 1H NMR (500MHz, 
MeOD) δ – 7.43(1H, s, N-C-CH-C-N+), 7.01(1H, m, Ar-CH-), 6.34(1H, m, Ar-CH-), 
6.21(1H, s, Ar-CH-), 3.20(2H, t, NH-C-CH-CH-CO-, J=6.9 Hz), 2.71(2H, t, NH-C-
CH2-CH-CO-, J=6.9Hz), 2.28 (3H, s, -CH3- ), 2.51 (3H, s, -CH3-); 13C NMR 
(500MHz, MeOD) δ – 176.2, 161.4, 158.4, 145.8, 134.9, 129.6, 125.8, 121.3, 
117.5, 34.0, 25.0, 14.9, 11.2. MS(ES-): m/z (%): 291.0 [M-H]-. 
5.1.24 – Synthesis of tert-butyl 3-bromopropylcarbamate67 –  
 
Following the procedure in literature67 and purification by flash chromatography 
(25% Ethyl acetate/Hexane) the compound was obtained in 80% yield. Rf (25% Ethyl 
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acetate/Hexane) = 0.5. 1H(500MHz, CDCl3) δ – 4.66(1H, b, -NH-), 3.43(2H, m, Br-
CH2-), 3.26(2H, m, Br-CH2-CH2-CH2-NH), 2.04(2H, m, -CH2-NH), 1.44(9H, s, -
(CH3)3-);  13C (500 MHz, CDCl3) δ – 156.6,  80.14, 39.73, 33.42, 31.43, 29.06. MS 
(ES+): m/z (%): 261.82 [M+Na]+. 
5.1.25 – Synthesis of 2-Azidoethylamine68 –  
 
Following the procedure in literature68 and purification by work-up as shown in 
literature the compound was obtained in 80% yields. Rf (10% MeOH/CH2Cl2) = 0.5. 
1H (500MHz, CDCl3) δ – 4.7(2H, bs, -NH2-), 3.34(2H, t, -CH2-N3, J=9.1Hz), 2.85(2H, 
t, -CH2-NH2, J=9.1Hz); 13C (500 MHz, CDCl3) δ – 66.5, 55.3, 41.9, 24.9, 15.9. MS 
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5.2  Thermal stability protocols – 
A pre-calibrated oven maintained at 37oC and 100% humidity was utilized for thermal 
stability study. Freezer at -20oC and 0% humidity and AR grade DMSO was utilized 
for preparing DMSO solution (100µL added for all samples) and solid for cold 
storage conditions. Samples were placed in eppendorf tubes and lid was closed during 
storage in the oven and freezer. The samples were analyzed for stability after 4 days, 
2months, 6months, 12months exposure to the above conditions using Shimadzu IT-
TOF LCMS instrument. ACN + 0.1% TFA / H2O + 0.1% TFA was used as the eluent 
in the reverse phase short column and the polarity was increased from 0% - 100% in a 
period of 25min. 2µL of sample (sample diluted with 1.5ml of HPLC grade MeOH) 
was injected for analysis and compared with the standard sample (diluted with 1.5ml 
of MeOH when required). This standard is not subjected to any of the above 
conditions and kept in freezer at 4oC.  
5.3   Macrophage studies protocols – 
Macrophages were prepared fresh by differentiation of THP-1 Monocytes using 
Phorbol 12-myristate 13-acetate (PMA) and used within 4 days for flow cytometry 
studies. Using the standard conditions as mentioned in Fig. 18-24, the cells were 
incubated with the probes and analyzed using Flow Cytometer (BD FACs Vantage 
SE). Varying concentrations of the probes from 5nM to 5µM were added to the fixed 
concentration of macrophages in cells along with 10µL of Propidium iodide (PI) to 
each cell for flow cytometry studies. The best concentrations of probes were chosen 
based on least cell death and maximum cell staining and used for confocal 
microscopy studies. Standard macrophage concentrations as described in Fig. 25 were 
prepared in glass base square shaped and the desired concentrations to be analyzed 
were added along with 60nM of Lyso-tracker red for confocal microscopy studies.   
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5.4   NCI 60 Cancer cell line protocols – 
5.4.1 Single Dose studies protocol – 
NCI 60 cancer cell line studies were done in collaboration with National Cancer 
Institute, USA50-53 are based on single dose response of the probes (Structures 48a and 
51). The concentration used for single dose testing is 10µM. The number reported for 
the one-dose assay is growth relative to the no-drug control, and relative to the time 
zero number of cells. This allows detection of both growth inhibition (values between 
0 and 100) and lethality (values less than 0). E.g. - a value of 100 means no growth 
inhibition; 40 would mean 60% growth inhibition; 0 means no net growth over the 
course of the experiment. A value of -40 would mean 40% lethality.  
5.4.2 Five Dose studies protocol 50-53 – 
The human tumor cell lines of the cancer screening panel are grown in RPMI  1640 
medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical 
screening experiment, cells are inoculated into 96 well microtiter plates in 100 µL at 
plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling 
time of individual cell lines. After cell inoculation, the microtiter plates are incubated 
at 37° C, 5 % CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of 
experimental drugs.  
After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a 
measurement of the cell population for each cell line at the time of drug addition (Tz). 
Experimental drugs are solubilised in dimethyl sulfoxide at 400-fold the desired final 
maximum test concentration and stored frozen prior to use. At the time of drug 
addition, an aliquot of frozen concentrate is thawed and diluted to twice the desired 
final maximum test concentration with complete medium containing 50 µg/ml 
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gentamycin. Additional four, 10-fold or ½ log serial dilutions are made to provide a 
total of five drug concentrations plus control. Aliquots of 100 µl of these different 
drug dilutions are added to the appropriate microtiter wells already containing 100 µl 
of medium, resulting in the required final drug concentrations.  
Following drug addition, the plates are incubated for an additional 48 h at 37°C, 5 % 
CO2, 95 % air, and 100 % relative humidity. For adherent cells, the assay is terminated 
by the addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 µl of 
cold 50 % (w/v) TCA (final concentration, 10 % TCA) and incubated for 60 minutes 
at 4°C. The supernatant is discarded, and the plates are washed five times with tap 
water and air dried. Sulforhodamine B (SRB) solution (100 µl) at 0.4 % (w/v) in 1 % 
acetic acid is added to each well, and plates are incubated for 10 minutes at room 
temperature. After staining, unbound dye is removed by washing five times with 1 % 
acetic acid and the plates are air dried. Bound stain is subsequently solubilized with 10 
mM trizma base, and the absorbance is read on an automated plate reader at a 
wavelength of 515 nm. For suspension cells, the methodology is the same except that 
the assay is terminated by fixing settled cells at the bottom of the wells by gently 
adding 50µl of 80 % TCA (final concentration, 16 % TCA). Using the seven 
absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the 
presence of drug at the five concentration levels (Ti)], the percentage growth is 
calculated at each of the drug concentrations levels. Percentage growth inhibition is 
calculated as:  
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz  
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz.  
Page 115 of 219 
 
 
Three dose response parameters are calculated for each experimental agent. “Growth 
inhibition” of 50 % (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which is the 
drug concentration resulting in a 50% reduction in the net protein increase (as 
measured by SRB staining) in control cells during the drug incubation. The drug 
concentration resulting in “total growth inhibition” (TGI) is calculated from Ti = Tz. 
The LC50 (concentration of drug resulting in a 50% reduction in the measured protein 
at the end of the drug treatment as compared to that at the beginning) indicating a net 
loss of cells following treatment is calculated from [(Ti-Tz)/Tz] x 100 = -50. Values 
are calculated for each of these three parameters if the level of activity is reached; 
however, if the effect is not reached or is exceeded, the value for that parameter is 
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A.1  Thermal stabilities of probes 57-63 – 
MS(E+)   Ret. Time : 16.193 -> 16.207 - 15.940 <-> 16.553 
 
Fig. 34 – Artelinic acid probe 57 thermal stability studies (Eluent  -  ACN : H2O) 

















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – -20oC, Humidity – 0% 
Structure 57 (4 days) 












Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 57 (Standard) 











Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 57 (4 days) 
Page 124 of 219 
 
 
MS(E+)   Ret. Time : 8.200 -> 8.213 - 8.153 <-> 8.280 
 
























Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 58 (4 days) 












Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 58 (Standard) 
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MS(E+)   Ret. Time : 11.753 -> 11.767 - 11.600 <-> 11.840 
 




























Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 59 (4 days) 









Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 59 (Standard) 
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MS(E+)   Ret. Time : 12.087 -> 12.100 - 11.960 <-> 12.120 
 























Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 60 (4 days) 









Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 60 (Standard) 






MS(E+)   Ret. Time : 16.293 -> 16.307 - 16.120 <-> 16.367 
 
 








































Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 61 (Standard) 
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 61 (4 days) 







MS(E+)   Ret. Time : 16.567 -> 16.580 - 16.413 <-> 16.660 
 
 
Fig. 39 – Probe 62 thermal stability studies (Eluent  - ACN : H2O) 


























Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 62(Standard) 
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 62 (4 days) 








MS(E+)   Ret. Time : 10.267 -> 10.280 - 10.027 
 
 
Fig. 40 – Probe 63a thermal stability studies (Eluent  - ACN : H2O) 
 
 


















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 63a (4 days) 










Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 63a(Standard) 






MS(E+)   Ret. Time : 4.353 -> 4.367 - 4.313 <-> 4.413 
 
 
Fig. 41 – Probe 63b thermal stability studies (Eluent  - ACN : H2O) 
 

















Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Temp – 37oC, Humidity – 100% 
Structure 63b (4 days) 





2.0 mAU(x100) 254nm,4nm (1.00)
Conditions 
Amount – 3mgs (95%) 
Injection Volume – 2 µL 
Structure 63b (Standard) 

































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 06:35:03




NS :            402
NUCLEUS : off
O1 :       13204.57 Hz
SFO1 :   125.7709936 MHz
SOLVENT : MeOD
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 DCQA1







































































































































































































































*** Acquisition  Parameters ***
DATE_t : 06:55:56




NS :            300
NUCLEUS : off
O1 :       13204.57 Hz
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 DCQA3
















































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        279.917 degree
PHC1 :          1.239 degree







































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            100
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         83.564 degree
PHC1 :         30.867 degree
13C AMX500 DCQA2 FRAC5





















































































*** Acquisition  Parameters ***
DATE_t : 06:03:47




NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
*** 1D NMR Plot Parameters ***
NUCLEUS : off







































































*** Acquisition  Parameters ***
DATE_t : 06:14:24




NS :            361
NUCLEUS : off
O1 :       13204.57 Hz
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 DCQA4 FRAC3






















































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        278.133 degree
PHC1 :          4.811 degree





























































































































13C AMX500  DCQA2 FRAC2 (MeOD)
































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:41:55




NS :            455
NUCLEUS : off
O1 :       13204.57 Hz
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 DCQA4 FRAC2






















































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         75.955 degree
PHC1 :         -1.330 degree













































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            313
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        104.921 degree
PHC1 :          8.569 degree
13C AC300 
MBA



































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        285.754 degree

















































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            371
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         78.148 degree
PHC1 :         32.814 degree
13C AMX500 MBBA















































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        142.897 degree
PHC1 :         -8.385 degree










































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            227
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         96.506 degree
PHC1 :         15.982 degree
13C Standard AC300  MBDOOA


































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        250.571 degree
PHC1 :          3.244 degree




















































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            168
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        171.072 degree
PHC1 :         30.187 degree
13C AMX500 MBDOOBA FRAC2









































































































































































































































































































































13C AMX500 FDA1 (MeOD)






































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :    300.1300000 MHz
BF2 :    300.1300000 MHz
BF3 :    300.1300000 MHz
DATE_t : 04:11:33
DATE_d : Jun 18 2009
INSTRUM : spect
NS :             16
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
PARMODE : 1D
SOLVENT : CDCl3
SW :        17.9519 ppm
TE :          297.3 K
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.30 Hz
MAXI :       10000.00 cm
MI :           0.00 cm
PC :           1.00
WDW : EM
*** 1D NMR Plot Parameters ***
AQ_time :      3.0408700 sec































































































































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :          18150
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         77.267 degree
PHC1 :         36.420 degree
13C AMX500  FDA3(FD8)







































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        193.418 degree





























































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            351
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -19.082 degree
PHC1 :         46.421 degree
13C AMX500 FAP































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        108.262 degree
























































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          17412
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        240.704 degree
PHC1 :         65.011 degree
13C AMX500 FAPA

















































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         95.337 degree
PHC1 :          5.538 degree






























































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            246
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         -2.222 degree
PHC1 :         53.925 degree
13C AMX500 FAPAC1 PURE

























































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        344.331 degree
PHC1 :          7.959 degree












































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            468
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        192.047 degree
PHC1 :         39.855 degree
13C AMX500 
FAPAC2 PURE






















































































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :              2
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          300.0 K
*** Processing Parameters ***
LB :           0.30 Hz





















































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :            257
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          300.1 K
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 CAPA1
































































































































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          300.0 K
*** Processing Parameters ***
LB :           0.30 Hz













































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :            335
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 CAPA2


















































































































































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :             16
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
TE :          300.0 K
*** Processing Parameters ***
LB :           0.30 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



























































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :          19933
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 FDA7 FRAC3
































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         99.731 degree























































































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          17998
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        243.238 degree
PHC1 :         18.619 degree
13C AMX500 FDA8 FRAC3















































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :          20854
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : DMSO
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         93.111 degree
PHC1 :          3.293 degree
13C Standard AC300 FD11



















































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          17742
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : DMSO
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         86.246 degree
PHC1 :         23.852 degree
13C AMX500  FDA6


























































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        288.229 degree
PHC1 :         -0.847 degree


































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            422
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         66.680 degree
PHC1 :         56.296 degree
13C AMX500 QAA3














































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
BF2 :    300.1300000 MHz
BF3 :    300.1300000 MHz
DATE_t : 08:06:42
DATE_d : Oct 13 2009
NS :              8
SOLVENT : MeOD
*** Processing Parameters ***
INTSCL :        1.00000
MI :           0.00 cm













































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
BF2 :    300.1300000 MHz
BF3 :     75.4677490 MHz
DATE_t : 08:09:15
DATE_d : Oct 13 2009
NS :          17909
SOLVENT : MeOD
*** Processing Parameters ***
INTSCL :        1.00000
MI :           0.00 cm
13C Standard AC300 ASC1 FRAC2


















































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        162.903 degree








































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            339
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         89.314 degree
PHC1 :         20.585 degree
13C AMX500 QAA4









































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 07:27:48
DATE_d : Oct 15 2009
DBPNAM0 :
NS :              8
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
LB :           0.30 Hz
*** 1D NMR Plot Parameters ***
Start :          16.48 ppm
Stop :          -4.18 ppm
SR :          13.06 Hz
AQ_time :      1.5859710 sec











































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 07:30:23
DATE_d : Oct 15 2009
DBPNAM0 :
NS :          18665
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
Start :         224.37 ppm
Stop :         -14.42 ppm
SR :           3.46 Hz
AQ_time :      1.0911740 sec
13C AMX500 ASC2 FRAC2































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        180.042 degree
















































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            822
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        200.563 degree
PHC1 :         61.478 degree
13C AMX500 CQ1MBA








































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        315.128 degree




















































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             51
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        214.619 degree
PHC1 :         33.507 degree
13C AMX500 CQ2MBA
















































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        153.570 degree




















































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           1592
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        302.023 degree
PHC1 :         35.690 degree
13C AMX500 CHLOBOD1










































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        117.169 degree
PHC1 :         -0.505 degree














































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            500
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         30.650 degree
PHC1 :          4.860 degree
13C Standard AC300 ARTELINIC ACID





































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        111.600 degree
PHC1 :          2.042 degree


















































































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            951
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         35.181 degree
PHC1 :          0.693 degree
13C AC300 Artelinate Coumarin Probe




















































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              2
NUCLEUS : off
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
TD :          32768
TE :          297.4 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    300.1295670 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



















































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            301
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         46.099 degree
PHC1 :        -13.736 degree
13C AC300 DCQA2 Alkyne



























































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        106.745 degree
PHC1 :         15.027 degree

































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :           3508
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : DMSO
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         16.111 degree
PHC1 :         23.969 degree
13C AC300 Coumarin Alkyne














































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        119.816 degree
PHC1 :         -5.772 degree





















































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            311
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         11.634 degree
PHC1 :         32.317 degree
13C AC300 COUMARIN AZIDE









































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        107.100 degree
PHC1 :          9.063 degree

































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            500
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         61.197 degree
PHC1 :        -31.818 degree
13C AC300 Artelinate Alkyne



























































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        113.413 degree





















































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            690
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         42.298 degree
PHC1 :         -7.515 degree
13C AC300 ARTAZ










































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              6
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        110.883 degree
PHC1 :          3.716 degree












































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            735
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         51.248 degree
PHC1 :        -21.226 degree
13C AC300 DCQA1 Alkyne






























































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        117.857 degree
PHC1 :         -5.279 degree



















































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            101
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         24.439 degree
PHC1 :         14.130 degree
13C AC300 DCQA3 Alkyne















































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        112.418 degree
PHC1 :         -0.100 degree






































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            101
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         28.612 degree
PHC1 :         11.913 degree
13C AC300 DCQA1 Dialkyne









































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        113.504 degree
PHC1 :         -0.995 degree































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            101
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         56.814 degree
PHC1 :        -29.857 degree
13C AC300 DCQA3 Dialkyne












































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        187.594 degree



































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            101
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        246.160 degree
PHC1 :         -8.974 degree
13C AMX500 CQAE






















































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              4
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        285.435 degree





























































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :             81
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -88.868 degree
PHC1 :          3.696 degree
13C CQ1AB














































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          300.0 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   500.1300140 MHz









































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             41
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :   125.7577060 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 CQABMs



































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          300.0 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off






























































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            100
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        218.028 degree
PHC1 :         34.068 degree
13C AMX500 3-bromo monobocamine


























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :             10
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : MeOD
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        138.785 degree
















































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            219
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : MeOD
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -63.527 degree
PHC1 :        -21.157 degree
13C CQMBPA













































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : DMSO
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        189.935 degree








































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            501
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : DMSO
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        260.302 degree
PHC1 :        -20.640 degree
13C AMX500 TAMBA




























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :   500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        184.330 degree

























































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :          12000
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        255.946 degree
PHC1 :        -23.885 degree
13C AMX500  Kunal-TAMART
































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
*** Processing Parameters ***
LB :           0.30 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off























































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          19177
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        309.975 degree
PHC1 :         26.453 degree
13C AMX500 BODIPY-FL
























































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
*** Processing Parameters ***
LB :           0.30 Hz

















































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :            140
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
TD :          65536
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 BODMBA

















































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
TE :          295.4 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300110 MHz









































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :            401
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        302.465 degree
PHC1 :         37.181 degree
13C AMX500 BODART








































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : DMSO
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        187.264 degree
PHC1 :         -6.068 degree



































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          23125
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : DMSO
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        212.858 degree
PHC1 :         34.181 degree
13C AMX500 TAMRA Alkyne





















































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
*** Processing Parameters ***
LB :           0.30 Hz





































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :            176
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
TD :          65536
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 BODALKYNE
























































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             32
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
TD :          32768
TE :          295.1 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   500.1300010 MHz

























































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :          20315
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
TD :          65536
TE :          295.2 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :   125.7576130 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 TAMAZ










































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        157.676 degree




































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            115
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        313.212 degree
PHC1 :         17.314 degree
13C AMX500 BODAZ

































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              2
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        155.223 degree
































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            201
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        323.253 degree
PHC1 :          4.414 degree
13C AMX500 CHLOBOD3
















































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        155.200 degree
PHC1 :         -0.012 degree



































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             51
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        293.549 degree
PHC1 :         51.731 degree
13C AMX500 Alpha Benzoxy Artem





































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          295.8 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off















































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            303
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        298.009 degree
PHC1 :         32.055 degree
13C AMX500 Beta-Allyl Deoxocarbaartemisinin

































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             32
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        265.195 degree
PHC1 :         13.662 degree















































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          19774
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        300.971 degree
PHC1 :         37.740 degree
13C AMX500 Beta DeoxoCarbaArtemisinin






























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        173.611 degree
PHC1 :        -13.366 degree































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            728
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        300.329 degree
PHC1 :         38.550 degree
13C AMX500 DCA COUM






































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             10
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        278.962 degree
PHC1 :          6.015 degree



















































































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          23777
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : MeOD
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        206.682 degree
PHC1 :         84.358 degree
13C AMX500 DCA BOD
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*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         75.855 degree
PHC1 :         -3.250 degree



















































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :             32
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        106.361 degree
PHC1 :         48.647 degree
13C AC300 Pyrrole Propionic ester Alkene










































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         76.715 degree
PHC1 :         -1.960 degree



















































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :             35
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        138.986 degree
PHC1 :         -5.715 degree
13C Standard AC300 CQAEMs



























































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        309.431 degree
PHC1 :         -2.096 degree









































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :             52
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        230.624 degree
PHC1 :          9.490 degree
13C AMX500

































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         26.955 degree
PHC1 :         -4.012 degree













































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :            510
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -15.591 degree
PHC1 :         41.815 degree
13C Standard AC300 DCA Alkyne













































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              2
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          295.7 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



























































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :            131
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          296.0 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :   125.7577060 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AMX500 DCA Azide
































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              2
NUCLEUS : off
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :   300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
TD :          32768
TE :          297.9 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :   300.1300130 MHz









































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             57
NUCLEUS : off
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
TD :          32768
TE :          297.9 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :     75.4677030 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off
13C AC300 Azido ethylamine




A.3  NCI 60 mean graph data – 
 
A3.1  Chloroquine diphosphate  parent molecule 
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A3.3  Artesunate parent molecule 
        
A3.4  Artesunate probe (51) vs Artesunate remaining NCI 60 comparision data – 
 
Fig. 42 – Mean graph data for parent molecule Artesunate (A3.3) and Comparision of 





























































A.4  LCMS data of compounds showing purity profile for Biotesting submission – All 
compounds submitted for bio-testing listed in this appendix have purity of 96% as observed 
on LCMS.  
 
Event#: 1 MS(E+)   Ret. Time : 16.880 -> 16.893 - 16.840 <-> 16.913   Scan# : 5065 -> 5069 




Event#: 1 MS(E+)   Ret. Time : 10.060   Scan# : 3019 
 







































Event#: 1 MS(E+)   Ret. Time : 8.720 -> 8.733 - 8.553 <-> 8.980   Scan# : 2617 -> 2621 - 













Event#: 1 MS(E+)   Ret. Time : 8.460 -> 8.473 - 8.333 <-> 8.753   Scan# : 2539 -> 
2543 - 2501 <-> 2627 
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Event#: 1 MS(E+)   Ret. Time : 8.860 -> 8.873 - 8.833 <-> 8.893  
 
 






























































                        Event#: 1 MS(E+)   Ret. Time : 9.720 -> 9.733 - 9.687 <-> 9.753    
 































                      Event#: 1 MS(E+)   Ret. Time : 8.533 -> 8.547 - 8.413 <-> 8.773    
 
 
Event#: 1 MS(E+)   Ret. Time : 12.423 -> 12.437 - 12.230 <-> 12.757    
 





































2.5 mAU (x1,000) 254nm,4nm (1.00)




Event#: 1 MS(E+)   Ret. Time : 12.240 -> 12.253 - 12.107 <-> 12.447    
 
Event#: 1 MS(E+)   Ret. Time : 16.593 -> 16.607 - 16.407 <-> 16.707    
 
 
















































MS(E+)   Ret. Time : 8.200 -> 8.213 - 8.153 <-> 8.280 






























































2.0 mAU (x1,000)254nm,4nm (1.00)
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2.5 mAU (x100)254nm,4nm (1.00)














MS(E+)   Ret. Time : 16.567 -> 16.580 - 16.413 <-> 16.660 
 
MS(E+)   Ret. Time : 10.267 -> 10.280 - 10.027 
 
































4.0 mAU (x100)254nm,4nm (1.00)








Event#: 1 MS(E+)   Ret. Time : 15.213 -> 15.227 - 14.893 <-> 15.253  
 















1.75 mAU (x1,000) 254nm,4nm (1.00)











2.0 mAU (x100) 254nm,4nm (1.00)








Event#: 1 MS(E+)   Ret. Time : 17.533 -> 17.547 - 17.253 <-> 17.613   




























                                Event#: 1 MS(E+)   Ret. Time : 9.760 -> 9.773 - 9.400 
 










2.25 mAU (x100) 254nm,4nm (1.00) 















4.0 mAU (x1,000)254nm,4nm (1.00)
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Event#: 1 MS(E+)   Ret. Time : 14.367 -> 14.380 - 14.033 <-> 14.400   Scan# : 4311 -> 4315 - 
4211 <-> 4321 
 
 
Event#: 1 MS(E+)   Ret. Time : 12.913 -> 12.927 - 12.893 <-> 12.947   Scan# : 3875 -> 3879 
- 3869 <-> 3885 
 
 































Event#: 1 MS(E+)   Ret. Time : 14.367 -> 14.380 - 14.033 <-> 14.400   Scan# : 4311 -> 4315 




Event#: 1 MS(E+)   Ret. Time : 12.193 -> 12.207 - 11.940 <-> 12.460   Scan# : 3659 -> 3663 
- 3583 <-> 3739 
 






































2.25 mAU (x100) 254nm,4nm (1.00) 




Event#: 1 MS(E+)   Ret. Time : 14.520 -> 14.533 - 14.140 <-> 15.253   Scan# : 4357 -> 4361 





Event#: 1 MS(E+)   Ret. Time : 14.947   Scan# : 4485 
 









































Event#: 1 MS(E+)   Ret. Time : 16.327   Scan# : 4899 
 
 
Event#: 1 MS(E+)   Ret. Time : 14.933 -> 14.947 - 14.660 <-> 15.287    
 





































Event#: 1 MS(E+)   Ret. Time : 14.767 
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